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ABSTRACT
Introduction- Most guidelines recommend multiple CD4 counts at different points in
time for both on ART and pre- ART patients. Because of this, the demand for CD4 count
is increasing as the ART program expands. But in low resource settings it is challenging
to have CD4 count easily due to the bottlenecks associated with technology selection,
laboratory infrastructure development, human resource limitations, cost-effectiveness,
instrument maintenance, and ensuring testing access and quality. Therefore predicting
the range of change of CD4 count after initiation of ART is important for patient
monitoring and AIDS prognosis prediction.
Objective- To build predictive model to forecast the ranges of CD4 count changes after
initiation of ART using  data mining that help build machine learning model that can
predict range of CD4 count changes and identify potential variables that predict CD4
count changes.
Methods- A retrospective follow up with Cross Industry Standard Process for Data
mining study was conducted. A total of 3104 adult ART users having at least two CD4
count values were considered.  The study used both the ART data base and reviewed
patient charts. Data was prepared for weka and inconsistencies, inaccuracies and
missing were handled. WEKA version 3 6 4 used and J48, Neural Network and Random
Forest algorithms were experimented.
Result- Of the 3104 patients who were on ART for about a median of 191.49 weeks,
78.2% of them succeeded to score CD4 count change values greater than 100 and
4.4% of patients score CD4 count change values less than zero. Among the algorithms
employed, RF with balanced class achieves 99.95% classification accuracy and j48 in
balanced data achieves 98.69% accuracy.
Conclusion and Recommendation- J48 can predict CD4 count changes in ART
clients within the acceptable level of accuracy and this algorithm can be used in low
resource setting as an option to predict CD4 count changes in a range. It can be used to
integrate the data base with Anti Retroviral treatment service.
11. INTRODUCTION
1.1 Statement of the problem
T-helper cells which are also known by the name CD4 cells are the coordinators of the
overall body’s immunological process. They take the central role of the immunological
system. These cells are known to help B cells produce antibody and augment cellular
immune response to antigens. CD is a contracted form for “Cluster of differentiation”
which is a protein found on the surface of the cells of the haematopoitic system. These
cells are the primary targets of HIV. After exposure to this virus it will replicate inside the
cell using the host’s cellular machinery. Then new virons will bud out through the cell
membrane and lyses the infected cell, causing the death of the infected CD4 cell and
these new virons infect other cells to continue the infection process and cause further
immunological paralysis(1).
The CD4 count is the main laboratory test conducted for both staging and monitoring
patients for ART. International and national guidelines advocate the use of CD4 count
for treatment decisions, as a predictor of disease progression, a criterion for treatment
initiation, and as a marker of treatment outcome in both adults and children. Therefore it
is recommended at multiple instants in the course of patient care. After tested for HIV,
positive results will go to CD4 count for staging the disease and assessing eligibility for
ART. Most guidelines say an adult patient is eligible for ART, if his/her CD4 count is less
than 200 or 350 cells per micro liter. After starting ART it is recommended to have CD4
counts every 3-6 months, but if a patient is not initially eligible, it is recommended to
have every 6-12 months. As ART program is expanding the need for CD4 count
becomes very high(2).
The effort for preventing HIV/AIDS ranges from behavioral intervention to introduction of
ART program(3). HAART is shown to be the most effective way of preventing
opportunistic infections and had significant impact on delaying the onset and
progression of AIDS. Once started, this treatment needs to be taken throughout lifetime,
and because of the associated side effects long term continuation is found to be a major
challenge.
2Because of this problem, WHO recommends the optimum time for initiating ART should
be guided by CD4 count and clinical staging. In developed countries plasma viral load
(viral load rising above 10,000 copies/µl) and CD4 counts are used to for monitoring and
assessment of initiating therapy(4). But in developing countries, where resources are
limited and access to advanced laboratory set up is not widely available, WHO clinical
staging is mainly followed to initiate therapy(4, 5). However, WHO continuously
advocates wider access to monitoring tools, particularly CD4 testing, to guide the
initiation and monitoring of ART(5).
A research done in South Africa however tells that treatment shall be initiated
immediately after one is known to be infected with HIV independent of CD4 or viral load
results, meaning to initiate therapy HIV status is enough.  And it claims this strategy
would save lives and resources that have been lost for CD4 and viral load monitoring by
the previous strategies(6). Our country Ethiopia uses WHO clinical staging which
recommends clinical stage 1 and 2 should have access to CD4 testing to decide when
to initiate treatment and CD4 count ≤350/mm3 irrespective of clinical stage for initiation
of therapies & patient monitoring; and patients with clinical staging 3 and 4 should start
treatment irrespective of CD4 count(7).
Predicting the changes of CD4 count that ART will come up with is a challenging task.
Because of the challenges related with technology selection, developing laboratory
infrastructure, human resource, cost-effectiveness, instrument cost and maintenance,
and ensuring testing access and quality. To see CD4 count changes, it need months or
years of follow up and serial measurements and comparison of CD4 counts. But, the
need to know these changes that will happen after a certain period of time of taking
ART is crucial and important for patient monitoring. If we know this, it would be very
helpful to look further our client’s future and to make some recommendations for better
progress, management and resource allocation. This can be done by data mining which
is less expensive, time saving and applicable to poor resource setting and its predictive
ability is shown to be effective in different literatures, as long as the good quality data
base is available. Therefore this study is going to apply data mining in the prediction of
the ranges of CD4 count changes.
31.2 Literature Review
This part is a review of different articles on data mining in general, and its application to
HIV/AIDS data in particular.
Data Mining
Data mining refers to the nontrivial extraction of hidden, previously unknown and
potentially useful information from data in databases. It is machine learning, statistical
and visualization techniques applied to discover and present knowledge in a form which
is easily generalizable(8). It is mainly concerned with learning from data or rather
turning data into information.(9).
Mining of gold from rocks or sand is termed as gold mining rather than rock or sand
mining. Thus, data mining should have been more suitably named as “knowledge
mining from data,” which is unfortunately somewhat long. “Knowledge mining,” a shorter
term may not reflect the emphasis on mining from large amounts of data. Mining is a
term used for finding a small precious material from large amount of raw material. Other
terms which do have similar or slightly different meanings with data mining are
knowledge mining from data, knowledge extraction, data/pattern analysis, data
archaeology, and data dredging(8).
There are different data mining techniques and functionalities that are dependent on the
type of pattern expected to be found on the data mining task. Generally, there are two
broad categories of data mining, namely Descriptive and Predictive. Descriptive mining
is the general characterization of properties of the data in the database. Predictive
mining tasks perform inference on the current data for making future predictions. Under
these categories there are different subtasks of data mining like Concept/Class
description, mining frequent patterns, association and correlations, classification and
prediction, Cluster analysis, Outlier analysis, evolution analysis are among the
notables(8).
It can also be categorized in to supervised and unsupervised concept learning methods.
Supervised learning builds classification models by forming concept definitions from
sets of data containing predefined classes. It builds models by using input attributes to
predict output attribute values. While unsupervised learning or clustering builds models
4from data without the aid of predefined classes were data instances are grouped
together based on a similarity scheme defined by the clustering system. In
unsupervised learning no target attributes are produced but rather giving a descriptive
relationship by using an objective function to extract clusters in the input data or
particular features which are useful for describing the data(9).
In another classification data mining is classified in to Directed data mining and
Undirected data mining. Classification, prediction and estimation are the techniques
used in directed data mining. Clustering, association rules, description and visualization
are techniques used in undirected mining. Directed data mining, supervised learning
and predictive modeling refer to the same concept. Whereas, Unsupervised learning,
undirected data mining and descriptive modeling refer to the same category(9).
The various subtasks of data mining use different mathematical data mining algorithms
or models. For instance for the task of classification and prediction like Decision tree
algorithms, Neural Network, and regression analysis can be used (8, 10). There are
also other algorithms like Support Vector Machine (SVM), Random Forests (RFs) and K
Nearest Neighbor.
Random forest was proposed by Breiman in 2001,  an additional layer of randomness
to bagging. To construct a tree in a forest, a different bootstrap sample of the data is
taken. In each node, it is split using the best among a subset of predictors randomly
chosen. It performs better compared to many other classifiers, including discriminant
analysis, support vector machines and neural networks, and is robust against over
fitting and imbalanced data sets(11).
Artificial neural network is a simulation to human brain. It is a set of processing units
called neurons. Inputs and outputs of the artificial neural network are a reflection of the
human nervous system. Neural Networks have been applied in a wide range of fields
like medicine, engineering, finance, etc. In medicine, neural network have been applied
to medical diagnosis, detection and evaluation of medical conditions and treatment cost
estimation. (12).
The task of prediction and classification need to be preceded by relevance analysis,
which attempts to identify attributes that do not contribute to the classification or
5prediction process. Those attributes which are not shown to have any important
contribution can then be excluded(8).
The purpose of data mining ranges from fraudulent detection to discovery of new
knowledge hidden in large data sets. It can be applied in a variety of fields including
business management, science, engineering, banking, and off course in medical and
health care data analysis and management(13).
Data mining and HIV/AIDS
The different algorithms of data mining can be applied to medical and health care
applications like HIV/AIDS. Some of these are discussed below.
Neural network model by back propagation algorithm is one of the methods in artificial
neural network. Multi layer feedback ward neural network model have been used in
many areas of medical application. A paper done in India in 2009 by Lilly F and
colleagues described the regimens specification for the HIV/AIDs patient’s, age group of
25-45 and also the patient is infected with in the initial stage of HIV/AIDS, based on the
patients’ unique factors like age, weight, HB, CD4, CD8. Using this multi layer feed back
ward neural network back propagation algorithm, the regimens specification for the
patient is calculated to approximately predict, how long the patient can extend his/her
life with this regimens. This method of Artificial Neural network is not time consuming
process compared to others. It can show the patient years of survival in two categories,
either >10 or <10 years(14).
Artificial neural networks (ANNs) have also been used for the classification and
prediction of the status of HIV/AIDS patients from symptoms. A research done in 2007
in South Africa by B. Leke Betechuoh and his colleagues using the data sets from
Demographic and medical data of the South African antenatal sero-prevalence survey
of 2001 showed that neural network can predict the educational level of individuals to an
accuracy of 88%, if the HIV status of individuals and other demographic characteristics
are known. This implies that it is possible to understand conversely that how modifying
the educational level of individuals can be used to control the proneness of individuals
to HIV infection. Also HIV status of individuals can be predicted given certain
demographic and socio-economic variables of the sero-prevalence survey information
6such as age, education, location, race, parity and gravidity. Using this design an
accuracy of 84.24% was obtained which means that the HIV status of an individual can
be predicted using demographic data to 84.24% accuracy. In other words, the results
showed that the MLP neural network architecture was quite efficient in predicting the
HIV status from demographic variables to 84.24% accuracy. Thus it is possible to nearly
accurately predict HIV status from demographic data(15).
In another research conducted in Malaysia by Kareem and colleagues in 2010 employs
classification and regression tree (CART) to predict the survival of HIV/AIDS patients.
The data set was taken from patients diagnosed and treated for HIV/AIDS at the
University Hospital, Kuala Lumpur from 1987 to 2007. A total of 998 (832 were male
and 166 patients were female) who had been diagnosed with AIDS were grouped
according to prognosis by CART. This algorithm was shown to be able to predict the
survival of AIDS with an accuracy of 60-93% based on selected dependent variables,
validated using Receiver Operating Characteristics (ROC).The receiver operating
characteristics (ROC) is used to determine the accuracy of predicted values. This study
concludes in order to survive 11 years; sex, ethnicity, marital status, weight, CD4 and
CD8 are important predictors for the survival of HIV/AIDS patients with a relative error of
0.404. The proposed model for Year 11 survival showed excellent performance with a
ROC value of 0.8166 and a percent accuracy of 77% and a train value of 0.8209(16).
There are also other attempts that applied machine learning to HIV/AIDS Bio
Informatics. A study done in UK compared three different machine learning tools ANN,
support vector machine (SVM) and random forests (RFs) to predict  virological response
to combination HIV therapy. Data from 1204 treatment change episodes (TCEs) were
identified from the HIV Resistance Response Database Initiative (RDI) database and
partitioned at random into a training set of 1154 and a test set of 50. The training set
was then partitioned using an L-cross validation scheme for training individual
computational models. There were seventy six input variables used. 55 baseline
genotype mutations; the 14 potential drugs in the new treatment regimen; four treatment
history variables; baseline viral load; CD4 count and time to follow-up viral load. The
output variable was follow-up viral load. Performance was evaluated in terms of the
correlations and absolute differences between the individual models' predictions and the
7actual DeltaVL values. And they found a result that is RF and SVM models can produce
predictions of virological response to HIV treatment that are comparable in accuracy to
a committee of ANN models. ANN models were significantly inferior to RF and SVM
model(17).
A workforce analysis research done by WHO Statistical Information System (WHOSIS)
2000, UN Fund for Development and Population Assistance (UNFDPA), the
International Council of Nurses, and the WHO/UNAIDS database,  to predict global
HIV/AIDS prevalence patterns, using data base obtained from the Global Human
Resources for Health Atlas 2004 showed that predictive data mining CART produces
very accurate results (greater than 95% accuracy) outcomes and even higher in the
case of some countries like Swaziland (100%)(18). Also predictive data mining was
applied to describe its feasibility to predict the survival of AIDS. An adaptive fuzzy
regression technique, FuReA, was used to predict the length of survival of AIDS
patients based on their CD4, CD8 and viral load counts. Predictive ability of FuReA was
measured and compared with fuzzy neural network prediction models. It is found that
both FuReA and fuzzy neural network models were able to predict the survival of AIDS
with an accuracy of 60% to 100% based on selected dependent variables(19).
Another important particularly related with range of CD4 count change after the initiation
of ART was done in South Africa by Singh and Mars in 2010 using datasets obtained
from the Stanford HIV drug resistance database (http://hivdb.stanford.edu/) which is
publically available and contains data from clinical trials. In this study a support vector
machine classification model that predicted the degree of CD4 count change was built.
The model used input variables like genome, current viral load and number of weeks
from baseline CD4 count and predicted the range of CD4 count changes. The changes
in CD4 count were grouped into four ranges of categories (∆CD4 < 0, 0≤∆CD4 ≤50,
51 ≤∆CD4≤100, ∆CD4 >100). This pilot project showed that a range of change in CD4
count accurately (accuracy rate 83%) predicted using SVM machine learning by using
attributes such as genotype, viral load and time. However, the study is limited because
it uses small number of data elements, other potential algorithms like neural network ,
regression trees, Random forests and other algorithms which are shown to learn
medical data well and that may outperform the SVM were not used(20).
8Despite efforts made to apply data mining in HIV/AIDS data, as far as the investigator’s
knowledge is concerned there are no published works that tried to apply data mining to
HIV/AIDS in Ethiopian context. Generally, the above mentioned literatures have tried to
describe that the importance and the possible applications of machine learning to health
sector research in general and HIV/AIDS research in particular worldwide.
91.3 Justifications
WHO health statistics 2011 reports the number of people living with HIV/AIDS grows to
an estimated 33.3 million in 2009, 23% higher than what was in 1999. The overall
growth of this pandemic remain stabilized and the new infection rate is 19% lower than
1999. The increasing number of people living with HIV is due to the wide use of life
prolonging effects of ART.  In December 2009, ART was available for more than 6
million people globally. Yet, availability of ART service coverage remain low (36%) in
low and middle income countries with significant variation across regions. Africa has
37% of ART coverage, with 3.9 million people are receiving ART(21).
The February 2010 Ethiopian monthly ART update report, reports there are cumulative
number of people ever started ART are 246,347 with significant variation in age groups.
Non pregnant females greater than 14 years of age account the highest number
(125,599)(22). The 2007 single point estimate reports the adult prevalence of HIV/AIDS
to be 2.7% in 2011(7.7% urban and 0.9% rural)(23).
As described above, the life expectancy of people living with HIV is increasing because
of the effects of ART. Initiation of therapy in our country is mainly guided by CD4 count
and WHO staging. And the need to follow patients taking ART is important to monitor
their progress. But following patients for a long period of time requires human, material
and financial resources. It requires serial measurement of CD4 counts, which is
complex cytometric procedure requiring highly standardized laboratory and well trained
professionals.
Since HIV/AIDS is known in our country, there is a huge, noisy scope of data produced
every day. But these large sets of data with complex and lots attributes are difficult to be
analyzed using the traditional statistical techniques. Identification of what is hidden in
these data sets, analysis of useful patterns and mining the important knowledge inside
the data calls for other higher analytical tools and technique, data mining .
The data mining algorithms which are shown to be effective in the prediction task can
be applied to predict what will be the changes in CD4 count for a patient starting ART,
provided certain patient attributes are available. ∆CD4 count is the difference between
base line CD4 and most recent follow up CD4 counts. The base line CD4 count is the
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initial CD4 count measured when a patient is ever enrolled on ART. There will be follow
up CD4 counts measured after being enrolled on ART to assess immune system
reconstitution. Therefore there will definitely be a change in CD4 counts, either
negative, zero or positive. This change if known initially is helpful. It will give us a clue to
assess treatment success and failure and if applicable can be used to determine drug
resistance. It also helps to understand HIV/AIDS dynamics during treatment. Therefore
this study is very important.
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2. OBJECTIVES
2.1 General Objective
To construct predictive model that enables to determine the ranges of CD4 count
changes after initiation of ART using the data mining approaches in Gondar University
Hospital, North West of Ethiopia.
2.2 Specific objectives
2.2.1 To identify attributes for prediction of CD4 count with domain expert
recommendations
2.2.2 To build predictive model that can predict CD4 count changes
2.2.3 To identify potential predictor variables that are needed to predict the ranges of
CD4 count changes.
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3. METHODS
3.1 Study Design
Retrospective follow up study with Cross Industry Standard Process for Data Mining
(CRISP-DM) was conducted.
3.2 Study area
This study was conducted in Gondar University Hospital in 2012. Gondar University
Hospital started free ART service since March 2005. In December 2012, the university
hospital reported a total of 6444 patients have ever enrolled for ART, among these 3888
(1561 male, 2327 female) were reported to be actively taking the treatment. 77 (36
male, 41 females) of the 3888 are taking second line the remaining 3412 are under first
line regimen. The hospital’s ART Clinic is constructed by 2 physicians,1 Master of
Public Health professional (RH), 2 Health Officers, 6 Nurses (2 Degree Nurse, 4
Diploma Nurses), 2 data clerks, 2 data base administrators, 3 case managers, 8
adherence counselors and 2 cleaners. The facility is linked with laboratory department
which has CD4 counting machines (1 Celldyn and 1 FACS Callybur CD4 counting
machines).
3.3 Source population
All HIV positive patient records and data base in the ART clinic, in Gondar University
Hospital.
3.4 Study population
All adult ART clients dataset which is registered in the ART data base and has baseline
and follow up CD4 counts was included in the study.
3.5 Study Period
This study was conducted from February to May 2012.
3.6 Inclusion criteria- all adult (age greater than 14) ART clients who started ART
and have baseline and follow up CD4 count after starting ART.
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3.7 Exclusion Criteria- Clients who started ART and their information is incomplete,
unreadable or their manual record is lost, and also clients who have not at least one
follow up CD4 count measure
In addition patients who are transferred in for ART service from elsewhere are not
included in this study because their data other than their baseline and recent CD4
count, required for the purpose of this study are incomplete when they are transferred in
to this hospital.
Clients whose medical record number is not written according to the new six digit
Ethiopian HMIS medical record number writing format are not also included.
3.8 Sample size and sampling procedures
From all the 3888 adults whoever started ART and actively taking the drug during the
time this investigation is undertaken, a total of 3104(79.8%) were included in this study.
The remaining 784 ART users were under the exclusion criteria and were not included.
3.9 Data collection procedures
The ART physician fills the ART laboratory request form and sends to the ART
laboratory. Then the laboratory data was collected from patients after measuring the
required hematologic and clinical chemistry parameters using flow cytometric methods
and chemical analysis by laboratory professional and manually enters the result in to
the request form or attaches a print out Clinical Chemistry and/or haematological result.
This data is collected on all patients at start of ART and periodically over the course of
the treatment and part of it is registered on ART data base. Also for each patient
demographic variables like employment, marital status, religion and educational status
are entered in the ART in take form by the ART Nurse or physician. Then some of these
data are transcribed in to the ART data base by the data base administrators.
The electronic data base was an MS access data base composed of many tables and
relationships including the baseline and the follow up tables. From this data base by
discussing with the domain expert (ART physician), numerous variables were advised to
be included that could potentially affect CD4 count change, but all the variables advised
were not available in the data base. But we think other variables have to be included,
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because the use of data mining is to uncover noble but previously unknown knowledge
that could be residing in large data bases. Then around 20 variables were taken from
the MS Access data base and changed in to the excel spread sheet format.
As discussed above, part of the data was collected from the ART data base, and it was
collected by the ART data base administrator, and the manually entered data was
collected by one ART Nurse working in the ART clinic and Card Clerk working together.
The data base which is collected for their own purpose does not include all the required
variables important for predicting the range of CD4 count change. That is why there was
a need to include excel manual extraction format prepared by the investigator for the
purpose of this research. One card clerk and one computer literate ART nurse entered
the manual extraction format from the patient card folders by taking out the patient card
folders from the archive department. At the same time, this manually extracted
document is appended with the electronic data sets by using the patient identifier code
called Medical Record Number. With this number, the data base and the data collected
from the manual patient card folder are connected together to produce one excel
spreadsheet data format with the required variables. From this excel sheet, some
variables like CD4 count change, time gap in a week were derived from the baseline
and follow up data using the excel insert function applications. The CD4 count change is
derived from the baseline and the current CD4 counts, by subtracting the baseline CD4
count from the current count. And the time gap in week, which is the time that ART user
has been on ART since he/she started is calculated by a formula inserted in the excel
insert formula application.
The formula comes from the idea that there are 7 days in a week, there are 30/4 weeks
in a month and there are around 52.14 weeks in a year. Using this concept, the formula
is derived. Day, month and year were written in Ethiopian calendar in separate columns
in excel sheet. The Ethiopian calendar has 13 months in one year and 30 days in each
month but the 13th month has only 5.25 days. Therefore the formula doesn’t work for the
13th month, Pagume. To avoid this problem, while entering the data , if we have any
date in Pagume (Ethiopian 13th month), we changed the ART start day by adding the
15
days in pagume, and the follow up date will also slide to another new date by
considering the number of days added.
Time gap = ((Follow up day – ART start day)/7 + (Follow up month – ART start
month)*30/4 + (Follow up Year – ART start year)*52.14)
Assume that, ART start day as “d1”, follow up day “d2”, ART start month “m1”, follow up
month “m2”, ART start year y1 and follow up year “y2”, the above long formula can be
simplified by the following equation.
Time gap = ((d2-d1)/7 + (m2-m1)*30/4 + (y2-y1)*52.14)
3.10 Data quality
The principal investigator gave training how to fill the manual extraction formats and
supervises the overall quality of data collection process and also the investigator was
together with the data collectors in almost all the time during the data collection
processes. While filling the excel manual extraction format part of the data was checked
by crosschecking the electronic based data sets with the paper based documents and
check out for matches and also many of the manually filled documents was cross
checked for similarity and consistency with the electronic data sets.
3.11 Variables of the study
3.11.1 Dependant variables (Class Attribute)
Range of CD4 count change
3.11.2 Independent variables
3.11.2.1 Socio demographic variables
• Age
• Sex
• Religion
• Marital status
• Educational status
• Occupation
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3.11.2.2 ART and HIV care variables
• Baseline CD4 count at the start of ART
• Day of the date when baseline CD4 count is measured
• Month of the date when baseline CD4 count is measured
• Year of the date when baseline CD4 count is measured
• Functional status (working, ambulatory, bedridden) at the start of ART
• WHO clinical staging at the start of ART
• Hemoglobin at the start of ART
• LFT at the start of ART
• RFT at the start of ART
• Weight when starting ART
• Pregnancy status during enrolment
• Recent CD4 count
• Day of the date when most recent CD4 count is measured
• Month of the date when most recent CD4 count is measured
• Year of the date when most recent CD4 count is measured
• Type of original regimen
• Type of current regimen
• Regimen change, when most recent CD4 count is measured (Yes, No)
• Number of weeks from the baseline CD4 count to the current CD4 count
• Change in CD4 count
3.12 Operational Definitions
∆CD4- it is the difference between base line CD4 and most recent follow up CD4 counts
∆CD4<0- The change in CD4 count is less than zero when the baseline CD4 count is
greater than the follow up CD4 count.
0 ≤ ∆CD4 ≤ 50- The difference between the two CD4 counts is between greater than
zero and 50.
51 ≤ ∆CD4 ≤ 100- The difference between the two CD4 counts is between greater than
51 and 100.
∆CD4 > 100- The change in the two CD4 counts is greater than 100.
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Time gap the difference between the date (MM/DD/YYYY) when 1st CD4 count is
measured at the start of ART and the date (MM/DD/YYYY)  when most up-to-date CD4
count is measured. It is calculated by the following formula entered in excel functions.
Time gap = ((d2-d1)/7+(m2-m1)*30/4+(y2-y1)*52.14)
3.13 Data processing and analysis
The MS excel 2007 spreadsheet format is then changed in to CSV format and then to
the ARFF to be suitable for the analysis software, weka 3 6 4. This software is a data
mining and knowledge management software and it is open source software developed
by the New Zealand intellects. This software is chosen because it can be freely
downloaded and accessed and because the principal investigator was trained during
the data mining and knowledge management course. The over all process of predicting
the range of change of CD4 count was mainly guided by the CRISP for data mining
guiding principles.
3.14 CRISP Methodology for data mining
CRISP was launched in late 1996 by three “veterans” of data mining market Daimler
Chrysler (then Daimler-Benz), SPSS (then ISL) and NCR. In order for the data mining
process to be reliable and standardized the CRISP methodology for data mining has to
follow step by step procedures. This methodology follows some predetermined
procedures briefly summarized by the figure below. Each step further consists of
several second-level tasks(24).
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Figure 1 CRISP data mining methodology steps(24)
Data
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3.14.1 Business Understanding
The first step in the CRISP data mining sequence is to deeply understand in the view of
business perspective(24).
HIV is a retro virus, hence a drug against this virus is known as Anti Retroviral drug, in
short ARV. Giving this drug in a correct way that is with support for adherence and
continuous monitoring is known by the name Anti Retroviral Treatment (ART). ARV
drug is a combination of three groups of antiviral drugs(25).
 NRTI:  'Nucleoside and Nucleotide Reverse Transcriptase Inhibitors' (divided into
NsRTI and NtRTI)
 the NNRTI: this stands for 'Non-Nucleoside Reverse Transcriptase Inhibitors'
 the PI: stands for Protease Inhibitors
Each drug has its own targets and process in the viral replication process(25)
The most commonly used antiretroviral drugs are summarized in table 1.
Table 1: commonly used antiretroviral drugs(25)
.
NRTI NNRTI PI
Nucleoside
reverse
transcriptase
inhibitors (NsRTI)
Nucleotide
reverse
transcriptase
inhibitor (NtRTI)
Non-nucleoside
reverse
transcriptase
inhibitors
(NNRTI)
Protease
Inhibitors (PI)
stavudine (d4T)
lamivudine (3TC)
zidovudine (AZT)
didanosine (ddI)
abacavir (ABC
tenofovir disoproxil
fumarate (TDF)
nevirapine (NVP)
efavirenz (EFV
saquinavir
(SQV/r) ritonavir
(RTV), as
booster* (/r)
indinavir (IDV/r)
nelfinavir (NFV)
lopinavir (LPV/r)
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To sustain the suppression of viral replication, to attack the virus in different ways and to
prevent or delay drug resistance; combination of these drugs are used. Therefore these
three in differently fortified and combined drugs become very powerful in preventing the
viral replication and opportunistic infections and in immune system reconstitution, above
all promoting the health condition of the patient. Hence these powerful antiretroviral
combination drugs are termed HAART to mean Highly Active Anti Retroviral Treatment.
What is the importance of this ART to the beneficiaries: among the many advantages
the following few can be shortlisted
 Prolong and improves the life of the patient
 Decrease morbidity, mortality and hospitalization
 Prevent mother to child transmission of HIV, etc.
First line and second line regimens
First line regimen: is prescribed to a patient who has never any previous ART
experience. It is a combination of two NRTI's and one NNRTI. The main first line
regimens currently in use are d4T-3TC-NVP, d4T-3TC-EFV, AZT-3TC-NVP, AZT-3TC-
EFV. But there are also special circumstance first line drugs. These are TDF-3TC-EFV
or NVP ABC -3TC-NVP or EFV.
Second line regimens
The second line regimen is a combination of 2 NRTIs (previously unused) + 1 PI. The
second line is known to be more effective but more pills need to be taken with food
restrictions and also more side effects.
The table below summarizes first line and second line drugs being used in Ethiopia the
following.
Table 2: first line and second line regimen
First line regimen Second line regimen for failure
D4T or ZDV
+
3TC
+
NVP or EFV
ddI or TDF
+
ABC
+
LPV/r or SQV/r or IND/r or NFV
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Since the establishment of ART service in Gondar University Hospital, it is following the
Federal Ministry of Health ART guideline. This ART service is one of the comprehensive
cares provided within the HIV care umbrella. The comprehensive cares include
Voluntary Counseling and testing (VCT), Prevention of mother to Child Transmission
(PMTCT), Tuberculosis (TB), and prevention and management of Sexually Transmitted
Diseases (STDs). These services are linked to each other.
When a patient is linked for ART service, the patient is assessed for medical eligibility.
Medical eligibility for ART is guided by Immunological and Clinical criteria. Before
starting the treatment, the patient has to be well prepared to take ART. He/she has to
understand that after starting this treatment once; it needs to be taken throughout.
Therefore the service provider prepares the patient for ART by treating other
opportunistic infections and also assesses the adherence conditions for the drug and
care. Adherence is the main problem in ART, because of the side effects associated
with the drugs and also the social problems related with HIV/AIDS. In Ethiopian ART
guideline, adherence is defined as “accepting, agreeing and correctly following a
prescribed treatment (participation of the patient)”
Requirements for a patient to be on ART: there are seven requirements currently
being used in the hospital for a patient to be enrolled on ART
1. HIV positive with written documentation: a patient who is referred from other
health service having a positive result
2. Medical eligibility: a patient is medically eligible for ART if CD4 < 200 regardless
of the clinical stage or WHO clinical stage 4 (no matter what CD4 count is) or
WHO clinical stage 3 (If CD4 < 350)
3. A patient fulfills the criteria to start ART by physician, health officer or nurse.
4. A patient treated or stabilized for any opportunistic infections
5. A patient who is ready for ARV therapy
6. Reliable drug supply: because ART is for lifelong treatment, sustainable drug
supply needs to be assured before starting this treatment to avoid emergence of
resistance.
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7. Supportive multidisciplinary team prepared for chronic care: provision of ART and
long term adherence requires multidisciplinary response(25).
3.14.2 Data Understanding
After understanding the overall business process going on in the ART clinic and
identifying business objectives and also the task of data mining, the next step in the
CRISP methodology which is data understanding takes the stage. This step started with
an initial collection of ART data and proceeds with activities related with getting familiar
with this data to identify and scout problems related with quality and also to crate
important subsets. The creation of subsets in the data is very important because it
eases the data mining task by simplifying and facilitating the pre processing stage.
The Gondar University Hospital ART related data is primarily entered in the manual
patient folder by the experts working in ART clinic. In collaboration with I-TECH
Ethiopia, an electronic based data management was established. This data base
consists of about 8 tables and relationships in MS Access, SQL form.  These tables
were carefully observed and with the recommendation of the domain expertise the two
tables become with the paramount importance for this investigation. These two tables in
the relationship are the “ART register table” (where the attributes and values are
entered when a patient starts ART for the first time) and the “ART follow up table” (this
is a table with attributes which respective values are entered every time the patient
comes for consecutive visits).
General overview, this data base is designed in a very good way. It tries to include
many attributes that have been entered manually in many patient ART formats. It was
established to ease access of the data and also to simplify and facilitate ART data
consolidation and reporting. The data base is the only electronic recording system
available from the many specialties in the medical domain, though there are some
emerging efforts to expand this kind of electronic data entry and handling system.
But the problem is this data base has many pitfalls. It doesn’t contain important baseline
and follow up variables like hemoglobin level, liver and renal function tests, etc, while
these information is being entered manually in many formats that are include within one
enclosed manual patient folder. The investigators have observed that this manual
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recording system crates the manual patient folder to be overburdened with large
amount of documents that are liable to damage, loss and mismanagement.
As described, the data base didn’t include all the important attributes recommended by
the domain experts; therefore there was a need to use the manual patient folder which
was one of the very tough tasks of this investigation.
The two tables in the data base are conjugated together to form one excel spreadsheet
and manually reviewed variables are entered in this excel work book after assendingly
sorting the MRN and looking for the variables and respective values in manual
document. By appending the manual variable and values with electronically produced
document and deriving some variables and values like CD4 count change, CD4 count
change Class and time gap between the current CD4 count and the time they started
ART, one excel spreadsheet that is suitable for this investigation was crated.
Data Description
The excel spread sheet contains 3104 records and 36 attributes, of which 3 of them are
derived (these are time gap, the CD4 count change and the CD4 count change class),
15 are taken directly from the data base and 17 attributes are added by manually filling
the excel workbook using the unique attribute MRN. Day, month and year were written
in Ethiopian calendar in separate columns in excel sheet to simplify calculation of the
time difference in a week.
Initially there were around 25 attributes taken from the two tables in the relational data
base, but the problem was 10 of them were with missing values more than 85%.
Therefore filling these missing attributes and their respective values manually was the
only option.
The attributes name, their data type and the possible values are described in table 3.
Attribute like age is categorized according to the WHO standard age classification to
simplify the data mining task and issues related with memories that could delay the data
mining process.
A means age values ranging 15-19
B means values ranging 20-24
C is values ranging 25-29
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D is values ranging 30-34, etc.
And CD4 count change is also categorized, note that the categorization is done
according to Yashik S. and M. Maurice 2010(20).
A is when a patient is on ART and have a CD4 count change greater than 100
B is when a patient is on ART and has a CD4 count change between 51 and 100
C is when a patient is on ART and has a CD4 count change between 1 and 50
D is when a patient was on ART and has a CD4 count change less than zero.
Table 3: Attribute, its description and possible subset of values in Gondar
University Hospital in April 2012
S.
No
Attribute Name Data
Type
Description Possible Values
1 Patient_HospitalCardNumber Number A Unique patient Identification Six digit according
to new EHMIS
2 Patient_CD4CountAdult Number CD4 cell count  at the starting
ART
Numeric
3 CD8_cellcount_attheStart
Of_ART
Number CD8 cell count at starting ART Numeric
4 plateletatthestart Number Platelet  Count at starting ART Numeric
5 HgbLevel_atStart Number Hemoglobin level when starting
ART
Real no.
6 CD4/CD8ratio_AtStartofART Number CD4/CD8 ratio when starting
ART
Real No.
7 LFT Nominal Liver Function Tests N, Elevated
8 RFT Nominal Renal Function Tests N, Elevated
9 EMPLOYEMENT Nominal Employment status of the
patient
NE(Not
Employed),
SE(Self
Employed),
E(Employed)
Retired, Farmer
10 MARITALSTATUS Nominal Marital Status of the patient Divorced, Married,
Separated, Single,
Widow/widower
11 education Nominal Educational status of the
patient
No, Primary,
Secondary,
Tertiary
12 religion Nominal Religion of the patient Orthodox, Muslim,
Catholic,
Protestant, Jewish
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13 ResidenceCondition Nominal Residence condition of the
patient
Urban, Rural
14 Patient_Gender Nominal Gender of the patient Male, Female
15 Residence Nominal Residence of the patient In Gondar(G),
Outside Gondar(O)
16 PatientPregnantAtEnrolleme
nt
Nominal Pregnancy status during
enrolment
False(F), True(T)
17 Patient_ARTStartDay Number The day component of the date
ART started
1-30
18 Patient_ARTStartMonth Number The month component of the
date ART started
1-12
19 Patient_ARTStartYear Number The Year component of the
date ART started
1995-2004
20 Patient_FunctionalStatus Nominal Patients Functional status when
starting ART
Working(W),
Ambulatory(A),
Bedridden(B)
21 Patient_Age Number Age of the patient when starting
ART
Numeric
22 Patient_WHOStage Nominal WHO stage of the patient when
starting ART
I, II, III, IV
23 Patient_Weight Number Weight of the patient when
starting ART
Real No.
24 Patient_OriginalRegimen Nominal Original Regimen AZT-3TC-EFV,
AZT-3TC-EFVKid,
AZT-3TC-NVP,
AZT-3TC-NVPKid,
d4t(30)-3TC-EFV,
d4t(30)-3TC-NVP,
d4t(40)-3TC-EFV,
d4t(40)-3TC-NVP,
OTHER
25 Patient_Regimen Nominal Current Regimen AZT-3TC-EFV,
AZT-3TC-NVP,
AZT-3TC-EFVKid,
d4t(30)-3TC-EFV,
d4t(30)-3TC-NVP,
OTHER,
RESTART
26 CurrentRegimenSimilarWithO
riginalRegimen
Nominal Current regimen similar with the
original regimen
Yes(Similar),
No(Not Similar)
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27 Patient_LastVisitTBScreen Nominal Last visit TB screening result N(negative),
P(positive)
28 Patient_ARVAdh Nominal ART Adherence Good(G), Poor(p)
29 Patient_CTXAdherence Nominal Cotrimoxasazole  Adherence Good(G), Poor(p)
30 RecentCD4Count Number Recent CD4 count of the
patient
Numeric
31 RecentCD4day Number The day component of the date
when most recent CD4 count is
measured
1-30
32 RecentCD4month Number The month component of the
date when most recent CD4
count is measured
1-12
33 RecentCD4Year Number The year Component of the
date when most recent CD4
count is measured
2003, 2004
34 TimeGap/weeks Number The time d/nce in weeks b/n
ART start date and Recent CD4
count date
Real No.
35 CD4countChange Number The CD4 count d/nce Integer
36 CD4ChangeClass Nominal Class of the change in CD4 fall A, B, C, D
3.14.3 Identifying Sources of Data (target data sets)
The principal investigator met with the GUH ART data sets administrators and the staffs
of the ART clinic and had discussions with them and subsequently identified the main
source of data. This source of data was supplemented by manually extracting some
remaining attributes from the paper based patient folder.
3.15 Data Preparation for Analysis
The data identified for data mining was collected, preprocessed, assessed,
consolidated, cleaned, transformed, missing values handled and changed to
appropriate format to be recognized by data mining techniques and data mining
software. The main data exist in Ms Access format and this form imported to Ms Excel
format, and then this data was changed into CSV (comma delimited) form. The data
mining software employed for analysis was WEKA 3.6.4. WEKA is a collection of java
based open source of many data mining and machine learning algorithms including pre-
processing on data, Classification, clustering, association rule extraction and it was
created by Waikato researchers in New Zealand(26). Its main features include
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 49 data preprocessing tools
 76 classification/regression algorithms
 8 clustering algorithms
 15 attribute/subset evaluators + 10 search algorithms for feature selection
 3 algorithms for finding association rules
 3 graphical user interfaces
– “The Explorer” (exploratory data analysis)
– “The Experimenter” (experimental environment)
– “The Knowledge Flow”(26).
This software can be downloaded for free from the provider’s website
http://www.cs.waikato.ac.nz/ml/weka/(27). It analyses data in the form of attribute
relation format. Therefore the CSV comma delimited format file was transformed in to
ARFF file format by opening the CSV format using Note pad program, then after setting
the relation name, attribute and its values as a header in the data, it was saved as
ARFF file. Part of the ARFF format is depicted in fig 2.
Descriptive statistics was done by using SPSS version 16 and the result of this
descriptive statistics is displayed in the two cross tabs by table
Data Cleaning: This step was challenging, time consuming and perhaps frustrating part
of mining ART data. As of any other data bases and data in other disciplines,
inconsistencies, inaccuracies and missing are inevitable in ART data. These problems
occur both in ART data base and in manual patient folder as well because of many
reasons. The probable reasons for these problems could be due to the following
1. Work overload- An overburdened physician may give priority to treating the
patient and registration and reporting may be compromised.
2. Equipment change- equipment may not be available at a period of time before.
For example Viral load data could be missing because the Polymerase Chain
Reaction (PCR) machine was not available.
3. Equipment used to measure might not be available or malfunctioning at the time
the data was to be entered. For example a patient might have started ART by
WHO staging so that the baseline CD4 count may be missing because the FACS
machine was not available or working during that day.
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4. The respondent may not be willing to disclose what is required during data
collection. A commercial sex worker might not be willing to speak her
employment condition to the ART Nurse due to different social reasons.
Inconsistency: an attribute could have values containing discrepancies in naming
or coding or it could be lacking standard. For example somebody may write
patient’s functional status as “Bedridden” and the other writes simply “B”, but
these two are understood in different ways in data mining.
Corrupted data like having a weight of 1kg is unacceptable, it is worth missing.
Inaccurate data like a CD4 count of 9999 is incorrect. The ART data base by
default imputes 99, 999, 9999, 88, 888 and 8888 for missing values. This has to
be changed to “?” for the data mining software to mean the data is missing.
To handle missing values, the following measures were taken.
 Finding the value in the manual patient folder and imputing the value
 But sometimes it could be severe, it could also be missing in the manual
patient document, so in this case depending on the characteristics of the
variable, the solutions used are
 Mode imputation for categorical variables
 Mean imputation for numeric variables
 The imputation techniques used above are done by the WEKA using the
unsupervised attribute filtering technique called ReplaceMissingValues.
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@Relation 'GUHospitalART-DataMining'
@Attribute Patient_HospitalCardNumber real
@Attribute Patient_CD4CountAdult real
@Attribute CD8_cellcount_at_theStartof_ART numeric
@Attribute platletatthestart numeric
@Attribute HgbLevel_atStart real
@Attribute CD4/CD8ratio_AtStartof_ART real
@Attribute LFT {N, Elevated}
@Attribute RFT {N, Elevated}
@Attribute EMPLOYEMENT {E, Farmer, NE, Retired, SE}
@Attribute MARITALSTATUS {Divorced, Married, Separated, Single, Widow/widower}
@Attribute education {No, Primary, Secondary, Teritiary}
@Attribute religion {Orthodox, Muslim, Catholic, Protestant, Jewish}
@Attribute ResidenceCondition {Urban, Rural}
@Attribute Patient_Gender {Male, Female}
@Attribute Residence {G, O}
@Attribute Patient_PregnantAtEnrollement {F, T}
@Attribute Patient_ARTStartDay {1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29,
30}
@Attribute Patient_ARTStartMonth {1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12}
@Attribute Patient_ARTStartYear {1995, 1996, 1997, 1998, 1999, 2000, 2001, 2002, 2003, 2004}
@Attribute Patient_FunctionalStatus {W, A, B}
@Attribute Patient_Age {A, B, C, D, E, F, G, H, I, J, K}
@Attribute Patient_WHOStage {I, II, III, IV}
@Attribute Patient_Weight real
@Attribute Patient_OriginalRegimen {AZT-3TC-EFV, AZT-3TC-EFVKid, AZT-3TC-NVP, AZT-3TC-NVPKid, d4t(30)-3TC-EFV,
d4t(30)-3TC-NVP, d4t(40)-3TC-EFV, d4t(40)-3TC-NVP, OTHER}
@Attribute Patient_Regimen {AZT-3TC-EFV, AZT-3TC-NVP, d4t(30)-3TC-EFV, d4t(30)-3TC-NVP, DROP, LOST, OTHER,
RESTART}
@Attribute CurrentRegimenSimilarWithOriginalRegimen {No, Yes}
@Attribute Patient_LastVisitTBScreen {N, P}
@Attribute Patient_ARVAdh {G, P}
@Attribute Patient_CTXAdherence {G, P}
@Attribute Recent_CD4Count real
@Attribute RcentCD4day {1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30}
@Attribute RecentCD4month {1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12}
@Attribute RecentCD4year {2002, 2003, 2004}
@Attribute TimeGap/weeks real
@Attribute CD4countChange integer
@Attribute CD4ChangeClass {A, B, C, D}
@Data
70,198,1600,302,12,0.12,Elevated,N,NE,Married,No,Orthodox,Urban,Female,G,F,1,6,1998,W,G,I,42.0,OTHER,OTHER,Yes,N,G,G,
895,29,6,2004,166.2771429,632,A
Figure 2: ARFF and sample data
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4. ETHICAL CONSIDERATIONS
Ethical approval was obtained from the institute of Public Health and college of
Medicine and Health Science, University of Gondar and support letter was obtained
from University of Gondar Hospital. This research was done using secondary data and
all study subjects within the ART data base are anonymiszed for the purpose of de-
identification and maintaining confidentiality. The data set is kept confidential and highly
secured by making the data shared to nobody else. It is protected by using password to
protect it from unwanted manipulations and unethical usage.
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5. RESULT
5.1. Socio-demographic characteristics
Out of the total 6444records of patients who ever started ART 3104 (48.2%) of them
were included in this study. Majority (60.9%) were females. The mean age of the clients
is about 33.5 years (SD 8.63). Majority of the clients (92.24%) were Orthodox Christians
and 49% of them were married. A significant number of clients (64.8%) were
unemployed.
Table 4: Socio-demographic characteristics and some selected ART baseline
variables of patients in Gondar University Hospital in April 2012
Variables Count %
Sex Male 1215 39.1
Female 1889 60.9
Age category 15-19 (A) 3 0.1
20-24  (B) 5 0.2
25-29 (C) 13 0.4
30-34 (D) 56 1.8
35-39 (E) 178 5.7
40-44 (F) 483 15.6
45-49 (G) 1145 36.9
50-54 (H) 520 16.8
55-59 (I) 328 10.6
60-64 (J) 213 6.9
65+    (K) 160 5.2
Residence
Condition
Rural 134 4.3
Urban 2970 95.7
Residence In Gondar 2502 80.6
Outside
Gondar
602 19.4
Educational status No 836 26.9
Primary 934 30.1
Secondary 947 30.5
Tertiary 387 12.5
Employment Employed 596 19.2
Farmer 134 4.3
Not Employed 2011 64.8
Retired 13 0.5
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Self Employed 350 11.2
Marital Status Divorced 693 22.3
Married 1521 49.0
Separated 87 2.8
Single 413 13.3
Widow/widower 390 12.6
Religion Catholic 2 0.06
Jewish 6 0.2
Muslim 212 6.8
Orthodox 2862 92.24
Protestant 22 0.7
Total 3104 100
Baseline and follow up ART characteristics
As shown in table 5, majority of patients (79.1%) started ART having “working”
functional status and 60.9% of patients started ART while they were in WHO stage III.
Just more than 37% of them were under AZT-3TC-NVP regimen. Table 5 shows the
detailed baseline and follow up Art characteristics of patients in Gondar University
Hospital
Table 5: ART characteristics of patients in Gondar University Hospital in April 2012
Variable Possible values Count %
Patient Functional
status
Bedridden 127 4.1
Ambulatory 521 16.8
Working 2456 79.1
WHO Stage I 311 10
II 500 16.1
III 1890 60.9
IV 403 13
RFT Elevated 91 2.9
N 3013 97.1
LFT Elevated 900 29
N 2204 71
Patient Pregnancy
status during
enrolment
T 35 1.1
F 3069 98.9
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Patient Original
regimen
AZT-3TC-EFV 371 11.9
AZT-3TC-EFVKid 1 0.03
AZT-3TC-NVPKid 2 0.06
d4t(40)-3TC-EFV 11 0.35
d4t(40)-3TC-NVP 35 1.1
d4t(30)-3TC-EFV 317 10.21
OTHER 547 17.6
d4t(30)-3TC-NVP 669 21.65
AZT-3TC-NVP 1151 37.1
Total 3104 100
Current regimen AZT-3TC-EFV 464 14.9
AZT-3TC-
EFVKid
1 0.03
AZT-3TC-NVP 1143 36.85
DROP 4 0.12
LOST 23 0.74
OTHER 974 31.4
RESTART 5 0.16
d4t(30)-3TC-EFV 155 5
d4t(30)-3TC-
NVP
335 10.8
Total 3104 100
Keys:  W   Working          F    False
A    Ambulatory     T    True
B    Bedridden       N    Normal
.
5.2. CD4 count changes occurred after initiation of ART
The CD4 count changes coming after initiation of ART with respect to the baseline
characteristics of the patient is described in table 5. The patients had a median initial
CD4 count of 139 cells/micro liter. The CD4 count change scored after initiation of ART
ranges from -544 to 1675, with a mean change of 243 (SD 191.14) and a median of 208
CD4 cells. The patients were on ART for a median of 191.49 weeks. The median recent
CD4 count is 358 cells/micro liters.
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Of the total clients on ART, 2427(78.2%) of them succeeded to score a CD4 count
change values of greater than 100, 336 (10.8%) of them scored a change between 51
and 100, 204(6.6%) of them have come with a change between 1 and 50. The
remaining, 137(4.4%) are those whose CD4 count is reduced from which it was when
they started ART that means they have scored a negative CD4 count change values
after initiated to ART as described in figure 3.
Keys: CD4 change greater than 100 CD4 change between 51 and100
CD4 change between 1 and 50 CD4 change less than zero
Figure 3 CD4 count change occurred by ART clients after initiation of ART in
Gondar University Hospital in April 2012
Table 6: ART Client’s variables measured according to the CD4 count change, in
Gondar University Hospital in April 2012.
A
A
B
C D
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CD4 change class
A % B % C % D % Total %
Patient
Gender
Male 1030 84.8 86 7.1 59 4.9 40 3.3 1215 100
Female 1397 74 250 13.2 145 7.7 97 5.1 1889 100
Residence
Condition
Rural 115 85.8 5 3.7 11 8.2 3 2.2 134 100
Urban 2312 77.8 331 11.1 193 6.5 134 4.5 2970 100
Residence Outside Gondar 483 80.2 66 11 31 5.1 22 3.7 602 100
In Gondar 1944 77.7 270 10.8 173 6.9 115 4.6 2502 100
Education No 619 74 104 12.4 70 8.4 43 5.1 836 100
Primary 735 78.7 99 10.6 66 7.1 34 3.6 934 100
Secondary 757 79.9 94 9.9 52 5.5 44 4.6 947 100
Tertiary 316 81.7 39 10.1 16 4.1 16 4.1 387 100
Employment Retired 12 92.3 0 0 1 7.7 0 O 13 100
Farmer 115 85.8 5 3.7 11 8.2 3 2.2 134 100
SE 290 82.9 27 7.7 21 6 12 3.4 350 100
E 500 83.9 56 9.4 24 4 16 2.7 596 100
NE 1510 75.1 248 12.3 147 7.3 106 5.3 2011 100
Marital Status Separated 64 73.6 11 12.6 6 6.9 6 6.9 87 100
Widow/widower 302 77.4 41 10.5 34 8.7 13 3.3 390 100
Single 316 76.5 42 10.2 25 6.1 30 7.3 413 100
Divorced 530 76.1 96 13.9 37 5.3 30 4.3 693 100
Married 1215 79.9 146 9.6 102 6.7 58 3.8 1521 100
Religion Catholic 2 100 0 0 0 0 0 0 2 100
Jewish 3 50 0 0 2 33.
3
1 16.7 6 100
Protestant 18 81.8 2 9.1 2 9.1 0 0 22 100
Muslim 174 82.1 15 7.1 12 5.7 11 5.2 212 100
Orthodox 2230 77.9 319 11.1 188 6.6 125 4.4 2862 100
Patient
Functional
status
B 101 79.5 11 8.7 6 4.7 9 7.1 127 100
A 387 74.3 64 12.3 46 8.8 24 4.6 521 100
W 1939 78.9 261 10.6 152 6.2 104 4.2 2456 100
WHO Stage I 219 70.4 46 14.8 33 10.
6
13 4.2 311 100
II 372 74.4 67 13.4 37 7.4 24 4.8 500 100
III 1504 79.6 190 10.1 111 5.9 85 4.5 1890 100
IV 332 82.4 33 8.2 23 5.7 15 3.7 403 100
RFT Elevated 77 84.6 7 7.7 2 2.2 5 5.5 91 100
N 2350 78 329 10.9 202 6.7 132 4.4 3013 100
LFT Elevated 698 77.6 106 11.8 53 5.9 43 4.8 900 100
36
N 1729 78.4 230 10.4 151 6.9 94 4.3 2204 100
Patient
Pregnancy
status during
enrolment
T 26 74.3 8 22.9 0 0 1 2.9 35 100
F 2401 78.2 328 10.7 204 6.6 136 4.4 3069 100
Patient
Original
regimen
AZT-3TC-EFV
300 80.9 29 7.8 25 6.7 17 4.6 371 100
AZT-3TC-
EFVKid 1 100 0 0 0
0
0 0 1 100
AZT-3TC-NVP 903 78.5 128 11.1 73 6.3 47 4.1 1151 100
AZT-3TC-
NVPKid
0 0 0 0 2 100 0 0 2 100
OTHER 404 73.9 60 11 43 7.9 40 7.3 547 100
d4t(30)-3TC-
EFV
244 77 38 12 19 6 16 5 317 100
d4t(30)-3TC-
NVP
538 80.4 75 11.2 39 5.8 17 2.5 669 100
d4t(40)-3TC-
EFV
7 63.6 3 27.3 1 9.1 0 0 11 100
d4t(40)-3TC-
NVP
30 85.7 3 8.6 2 5.7 0 0 35 100
Current
regimen
AZT-3TC-
EFVKid
1 100 0 0 0 0 0 0 1 100
DROP 3 75 0 0 0 0 1 25 4 100
RESTART 5 100 0 0 0 0 0 0 5 100
LOST 15 65.2 3 13 4 17.
4
1 4.3 23 100
d4t(30)-3TC-
EFV
133 85.6 11 7.1 8 5.2 3 1.9 155 100
d4t(30)-3TC-
NVP
268 80 46 13.7 11 3.3 10 3 335 100
AZT-3TC-EFV 355 76.5 46 9.9 38 8.2 25 5.4 464 100
OTHER 746 76.6 106 10.9 67 6.9 55 5.6 974 100
AZT-3TC-NVP 901 78.8 124 10.8 76 6.6 42 3.7 1143 100
Current
Regimen
similar with
original
regimen
No 797 76.6 111 10.7 76 7.3 56 4.4 1040 100
Yes 1630 79 225 10.9 128 6.2 81 3.9 2064 100
Last Visit TB
screen Result
P 47 75.8 6 9.7 7 11.
3
2 3.2 62 100
N 2380 78.2 330 10.8 197 6.5 135 4.4 3042 100
ARV G 2426 79.1 336 11 204 6.6 102 3.3 3068 100
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Adherence P 1 2.8 0 0 0 0 35 97.2 36 100
CTX
Adherence
G 2426 78.9 336 10.9 204 6.6 108 3.5 3074 100
P 1 3.3 0 0 0 0 29 96.7 30 100
Total 2427 78.2 336 10.8 204 6.6 137 4.4 3104 100
5.3. Model Building by WEKA 3 6 4
Different experiments were carried out to build the model. These experiments are based
on two different attribute and instance combinations (input). These inputs are
A. Input 1:  using the original data with 27 attributes (including the class attribute)
and the total 3104 instances(2427, 336, 204, 137 values for the CD4 count
change classes of A, B, C and D respectively)
B. Input 2: using balanced data with SMOTE (Synthetic Minority Over Sampling
Technique) having 27 attributes. In principle, imbalanced data cause machine
learning difficulties and also decrease classifying algorithm’s performance;
because the minority class or the rarely occurred classes (as happened in D or
137 in the above case) values will be misclassified to the majority class
occurrences, because the classifier will be overwhelmed with the majority class
and ignores the minority class(28). Therefore after trying more than 23 levels of
different SMOTE algorithms, the 19th level of SMOTE make the class
approximately balanced better than any other levels tried. So that in the 19th level
of SMOTE balanced data, the number of instances became 42,284 and is
summarized by table 7. But there was a problem of taking too much time in
building the models specially in the neural network.
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Table 7: CD4 count change class with respective to the SMOTE balanced class values
Class Class values Percentage
A 9,708 23
B 10,752 25.4
C 13,056 30.9
D 8,768 20.7
Total 42,284 100
So that for each algorithm, these two inputs in 10% cross validation and also 90/10
training/ testing test options are done making 4 experiments for one machine learning
algorithm employed to predict CD4 count changes, totaling 10 experiments were
conducted for three different predictive models.
Test Option 1: 10% cross validation
Test Option 2: default 90/10 training/ testing split
Experiment 1: J48 algorithm with input 1and 10 fold cross validation applied to
imbalanced data (original data)
Experiment 2: J48 algorithm with 90/10 training test applied to imbalanced data
(original data)
Experiment 3: J48 algorithm with input 2 and 10 fold cross validation, using
SMOTE balanced data
Experiment 4: J48 algorithm with input 2 and 90/10 training/testing split, using
SMOTE balanced data
Then after applying the above different 4 combination, the following results
clearly shown in the table 8 are obtained.
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Table 8: input combinations and respective J48 outputs
Expe
rime
nt
Test Name No. of
attributes
used
Instanc
es used
Size of
the
tree
No.
of
leave
s
Time taken
to build the
model(in
seconds)
Accuracy
achieved
1 Experiment 1 27 3104 304 208 0.64 79.9936
2 Experiment 2 27 3104 304 208 0.3 87.8222
3 Experiment 3 27 42284 1989 1308 12.77 96.5968
4 Experiment 4 27 42284 1989 1308 12.72 98.6922
J48 decision tree with SMOTE balanced data register a very good accuracy is attributed
by the balancing the imbalanced data, in principle imbalanced nature of the data
reduces classification accuracy. J48 tree can be better described with the a tree that is
developed to show which patient with which attributes could have what kind of CD4
count change. Part of the large tree developed for the best working, J48 decision tree
with input 2 test option 2, part of it is well presented by figure 4.
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J48graft pruned tree
------------------
Patient_Age = A
| Patient_ARVAdh = P: D (0.0|83.0/1.0)
|   Patient_ARVAdh != P
|   |   Patient_CD4CountAdult <= 688.03694
|   |   |   HgbLevel_atStart <= 19.05
|   |   |   |   Patient_CTXAdherence = P: D (0.0|30.0/1.0)
|   |   |   |   Patient_CTXAdherence != P
|   |   | |   |   platletatthestart <= 50.594004: D (0.0|11.0)
|   |   |   |   |   platletatthestart > 50.594004
|   |   |   |   |   |   HgbLevel_atStart <= 3.85: A (0.0|9.0)
|   |   |   |   |   |   HgbLevel_atStart > 3.85
|   |   |   |   |   |   |   Patient_Regimen = d4t(30)-3TC-EFV: A (0.0|220.0/22.0)
|   |   |   |   |   |   |   Patient_Regimen != d4t(30)-3TC-EFV
|   |   |   |   |   |   |   |   platletatthestart <= 752
|   | |   |   |   |   |   |   |   EMPLOYEMENT = Farmer: A (0.0|171.0/19.0)
|   |   |   |   | |   |   |   |   EMPLOYEMENT != Farmer
|   |   |   |   |   |   |   |   |   |   EMPLOYEMENT = Retired: A (0.0|13.0/1.0)
|   |   |   |   |   |   |   |   |   |   EMPLOYEMENT != Retired
|   |   |   |   |   |   |   |   |   |   |   ResidenceCondition = Rural: A (0.0|136.0/19.0)
|   |   |   |   |   |   |   |   |   |   |   ResidenceCondition != Rural
|   |   |   |   |   |   |   |   |   |   |   |   CD8_cellcount_at_theStartof_ART <= 130.896199: A (0.0|59.0/8.0)
|   |   |   |   |   |   |   |   |   |   |   |   CD8_cellcount_at_theStartof_ART > 130.896199
|   |   |   |   |   |   |   |   |   |   |   |   |   EMPLOYEMENT = SE: A (0.0|418.0/64.0)
|   |   |   |   |   |   |   |   |   |   |   |   |   EMPLOYEMENT != SE
|   |   |   |   |   |   |   |   |   |   |   |   |   |   RFT = Elevated: A (0.0|91.0/14.0)
|   |   |   |   |   |   |   |   |   |   |   |   |   |   RFT != Elevated
|   |   |   |   |   |   |   |   |   |   |   |   |   |   |   Patient_OriginalRegimen = d4t(40)-3TC-NVP: A (0.0|35.0/5.0)
|   |   |   |   |   |   |   |   | |   |   |   |   |   |   Patient_OriginalRegimen != d4t(40)-3TC-NVP
|   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   Patient_FunctionalStatus = B: A (0.0|131.0/26.0)
|   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   Patient_FunctionalStatus != B
|   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   religion = Protestant: A (0.0|22.0/4.0)
|   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   religion != Protestant
|   |   |   |   |   |   |   |   | |   |   |   |   |   |   |   |   |   Patient_LastVisitTBScreen = P: A (0.0|62.0/15.0)
|   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   Patient_LastVisitTBScreen != P
|   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   | |   |   MARITALSTATUS = Separated: A (0.0|88.0/24.0)
|   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   MARITALSTATUS != Separated
|   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   education = Secondary: C (0.0|10979.0/3762.0)
|   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   education != Secondary
|   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   Patient_WHOStage = IV: A (0.0|1055.0/379.0)
|   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   Patient_WHOStage != IV: C (3.0/1.0)
|   |   |   |   |   |   |   |   platletatthestart > 752: A (0.0|7.0)
|   |   |   HgbLevel_atStart > 19.05: A (0.0|18.0)
|   |   Patient_CD4CountAdult > 688.03694: B (0.0|47.0/1.0)
Patient_Age = B
|   Patient_ARVAdh = P: D (0.0|83.0/1.0)
|   Patient_ARVAdh != P
|   |   Patient_Weight <= 23.697703: A (0.0|37.0)
|   |   Patient_Weight > 23.697703
|   |   |   Patient_CD4CountAdult <= 688.03694
|   |   |   |   HgbLevel_atStart <= 19.05
|   |   |   |   |   Patient_CTXAdherence = P: D (0.0|30.0/1.0)
Figure 4: Part of the J48 decision tree
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But the problem is the size of this tree is very big and hence it will be very difficult to
generate rules. To solve this problem, we need to set the MinNumObj to 5 by which the
default was 2. This means the process of classifying continues until the numbers of
instances reach 5. But this has disadvantages as it compromises the classification
accuracy. It downgrades from 98.69% to 82.1% while reducing the size of the tree
from1989 to 1421. The j48 tree for this classification provide the following rules
extracted from the decision tree, the whole tree is annexed in annex iii.
Some of the important rules which can be extracted from the decision tree
presented in annex III can be presented in the following way.
1. If patient age is between 35 and 39, Liver Function Test Normal, functional status
working and patient original regimen is AZT-3TC-EFV→the CD4 count change
expected will be greater than 100.
2. If patient age is between 35 and 39, Liver Function Test Normal, functional status
working, patient original regimen AZT-3TC-NVP, patient gender female, WHO
stage II, educational status No, Marital status Married and CD8 cell count is greater
than or equal to 489→the CD4 count change will be between 51 and 100.
3. If patient age is between 40 and 44, Gender is male and functional status is working
→ the CD4 count change will be greater than 100
4. If patient age is between 40 and 44,  female, unemployed, WHO stage is II, initial
regimen is AZT-3TC-NVP, elevated LFT, CD4/CD8 ratio  0.096→The CD4 count
change will be less than zero.
5. If patient age is between 45 and 49, Education No, Liver Function Test Normal,
Current regimen not similar with the original, Patient original regimen is d4t(30)-
3TC-NVP, CD8 cell count at start of ART is greater than or equal to 1123
cells/micro liter, Hemoglobin level, is less than or equal to 13 mg/dl and the time
gap is less than or equal to 200.97 weeks → the CD4 count change will be less
than zero. Etc.
So that, this kind of rules can be extracted from the decision tee and used in predicting
the CD4 count change in ART users.
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Those serial experiments with the two test options showed that the best accuracy
measured is scored by the J48 in Experiment 4 which is about 98.69% that means it
correctly classified the 98.69% (41,731) of the instances from the total number of
SMOTE balanced instances of 21,142, but the time taken to build the model is
somewhat higher than the other three. About 553 instances (1.3%) are incorrectly
classified.
The above test combinations and experiments are applied similarly for Neural Network
classification algorithm, as shown in table 9.
Table 9: input combinations and their respective Neural Network output
Experiment Test No. of
attributes
Used
Instances
used
Time taken
to build the
model in
seconds
Accuracy
achieved
1 Experiment 1 27 3,104 352.05 75.741
2 Experiment 2 27 3,104 350.66 94.201
3 Experiment 3 27 42,284 4693.67 95.4687
4 Experiment 4 27 42,284 5112.05 96.6252
Table 9 describes that the best classification accuracy in Neural Network is achieved by
applying neural network in SMOTE balanced data with tuning the test option to 90/10
training/testing test mode. It is shown that this test classifies the SMOTE balanced data
correctly with accuracy of 96.62% that means 40,857 instances are correctly classified.
And also these experiments are repeated also by using Random Forest algorithm and
table 10 describes about the output.
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Table 10: Input combination and respective RF output
Experiment Test No. of
attributes
Used
Instances
used
Time taken
to build the
model in
seconds
Accuracy
achieved
1 Experiment 1 27 3,104 0.53 99.549
Note that here there is no need to cross validate Random Forest to get unbiased
estimate of the test set error because it is estimated internally, while leaving out one
third of the data (37%) in the boot strap. And also there is also no need to balance the
imbalanced data sets Therefore there are no experiment done using RF test with cross
validation and balanced data sets. Thus, only one experiment is conducted for random
forest.
Then we need to compare the three algorithms to find out which algorithm works best in
classifying the data. In fact, three algorithms achieve very good accuracies. In the case
of J48 and Neural network, the SMOTE balanced data is more correctly classified than
the imbalanced data. By comparing the J48, Neural Network and RF (Random Forest);
RF in even in unbalanced data outperforms J48 and Neural Network with a best
accuracy (accuracy of 99.95%). In the J48 and neural network in unbalanced data
smaller accuracy was registered (79.99% and 75.7% respectively). As we can clearly
observe from table 11, all the performance robustness measures of random forest
reflect its supreme performance over J48 and neural Network. But random forest simply
builds a forest not a single tree by randomly selecting the square root of “n” number of
variables, because of this it is difficult to extract rules and select variables from random
forest.
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Table 11: Classification accuracy of the best working model RF
Class TP rate FP rate Precision Recall ROC Area
A 1 0.021 1 0.997 1
B 0.973 0 0.973 0.986 1
C 0.99 0 0.99 0.995 1
D 0.978 0 0.978 0.989 1
Weighted av 0.995 0.016 0.995 0.995 1
.
Therefore the 2 better classifying models of J48 an Neural Network are revaluated; the
J48 model with Experiment 4 and 90/10, the Neural network in Experiment 4 and 90/10
training/testing to train the data again by assigning the test options in 90/10
testing/training split. Therefore the target data set is supplied for the models and
analyzed with this test option and achieves a classification accuracy of 87.11 and 83.54
for J48 and Neural Network respectively. Confusion Matrices of the two evaluation
models are presented by table 12and 13 respectively. Because RF already registered
excellent accuracy in unbalanced data sets, the reevaluation test for random forest is
not important.
Table 12: Confusion matrix showing the reevaluation of most accurate J48
supplied with the original data with the 3104 instances
Classified as
Actual A B C D Total Percentage
accuracy
A 2318 44 34 31 2427 95.5
B 119 198 12 7 336 58.9
C 63 20 117 4 204 57.4
D 46 9 11 71 137 51.8%
Total 2546 271 174 113 3104 87.11
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As we can see from table 11, it classifies CD4 count changes falling a change more
than 100 with 95.5%, but the other accuracies for CD4 count changes less than zero,
between 1 and 50 and between 51 and 100 are quite lower and the overall accuracy is
87.11.
Similarly the best model of the Neural Network which is the Neural Network model
which classified the data with SMOTE balanced data with 90/10 training/testing split is
displayed on table 13
Table 13: Confusion matrix showing the reevaluation of most accurate Neural
Network supplied with the original data with the target data sets
Classified as
Actual A B C D Total Percentage
accuracy
A 2310 42 45 30 2427 95.2
B 158 145 18 15 336 43.2
C 101 19 72 12 204 35.3
D 54 9 8 66 137 48.2
Total 2623 215 143 123 3104 83.54
Table 12 shows, Neural network achieves a classification accuracy of 95.2%, 43.2%,
35.3% and 48.2% for A, B, C and D respectively. And the overall accuracy is 83.54 %
which is lower than the decision tree.
Therefore we can deduce that random forest correctly classifies the range of CD4 count
changes accurately. The result displayed in table 10 is random forest of 10 trees
constructed using five random features. The out of bag error is 0.2336 and the time
taken to build the model is 0.53 seconds. Note that the out of bag error comes from the
out of bag data. When the training set used to build the tree by using sampling with
replacement, one third of the cases are left out of sample(out of bag data). This data is
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then used to get a running unbiased estimate of the prediction error while trees are
added to the forest.
By comparing the classification performance accuracies of the three algorithms, we can
generalize that RF model applied in unbalanced data, works well with the original 3104
instances data and produce about 99.95% accuracy. As we can understand from this
percentage, it nearly perfectly classifies the data accurately. Off course classification
algorithm with high accuracy doesn’t necessarily mean that better performance on
target data set. Other evaluating mechanisms like Area under the ROC measure are
better robustness measure. So that for highly imbalanced data the Area under ROC
(AUC) is the good performance metric. AUC is the probability that a classifier ranks a
randomly chosen positive instance higher than a negative instance(29). ROC curve is
true positive rate (Sensitivity) plotted in function of the false positive rate (100-
Specificity)(30, 31).
The RF with accuracy of 99.95% scores an AUC of value of 1 which means it perfectly
classifies the data, J48 with accuracy of 87.11% scores a reasonable AUC of value of
0.938 and the Neural Network with the 83.54 accuracy has an AUC value of 0.812.So
that the AUC also revealed that RF works best for classifying the CD4 count changes.
The percent agreement or the kappa statistic is also excellent (98.77%) as it achieves
almost perfect percentage agreement between the CD4 count change predicted by the
model and the CD4 count change actually is. The detailed classification accuracy can
of random forest is summarized in table 14.
Table 14: Confusion matrix showing the detailed classification accuracy of RF
Classified as
Actual A B C D Total Percentage
accuracy (%)
A 2427 0 0 0 2427 100
B 9 327 0 0 336 97.3
C 2 0 202 0 204 99
D 3 0 0 134 137 97.8
Total 2441 327 202 134 3104 99.5
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The AUC for RF classification for each class are displayed by the following figures.
Because the AUC value for all classes are 1, the ROC graphs are the same for all
classes therefore only one figure is displayed below and others left are the same as the
fig 5.
tpr
fpr
Figure 5 ROC curve for CD4 count change
This curve shows that in each of them, the AUC is 1 to mean that RF achieves perfect
performance in classifying the CD4 count changes accordingly. Note that the straight
line drawn on all ROC curves is a line that is for random guess.
Attribute selection
Applying the Ranker + InfoGainAttributeEval method of attribute selection method, the
following table ranks attributes according to their importance in classifying the CD4
count change, Note that ranking is done by using the Information Gain values.
Ranked attributes:
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Table 15: Attribute rank and its information Gain
Rank Attribute Information gain score
1 Patient_Age 0.355846
2 Education 0.281198
3 CD4/CD8ratio_AtStartof_ART 0.259066
4 CD8_cellcount_at_theStartof_ART 0.249143
5 Patient_OriginalRegimen 0.239833
6 Patient_Regimen 0.212706
7 HgbLevel_atStart 0.197933
8 MARITALSTATUS 0.164389
9 Patient_Gender 0.155603
10 Patient_CD4CountAdult 0.151298
11 Platletatthestart 0.144812
12 TimeGap/weeks 0.119318
13 CurrentRegimenSimilarWithOriginalRegimen 0.084873
14 LFT 0.081058
15 EMPLOYEMENT 0.068596
16 Patient_WHOStage 0.054502
17 Patient_FunctionalStatus 0.026612
18 Patient_Weight 0.023363
19 Residence 0.021713
20 Religion 0.005935
21 Patient_ARVAdh 0.004278
22 ResidenceCondition 0.004228
23 RFT 0.002742
24 Patient_CTXAdherence 0.001459
25 Patient_LastVisitTBScreen 0.001353
26 Patient_PregnantAtEnrollement 0.000946
The other methods tried to evaluate attribute that are important to predict D4 count are
Best First +CFS Subset Eva and Random Search +CFS Subset Evaluator. The two
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methods agree that the following are subset of attributes important in predicting the CD4
count change.
• HgbLevel_atStart
• CD4/CD8ratio_AtStartof_ART
• LFT
• MARITALSTATUS
• Education
• Patient_Gender
• Patient_Age
• Patient_WHOStage
• Patient_OriginalRegimen
• Patient_Regimen
• Patient_CTXAdherenc
• TimeGap/weeks
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6. DISCUSSION
We can observe the detailed classification accuracies presented in table 10 and 111. It
is clearly shown that the Random Forest algorithm predicts CD4 count change better
than any other algorithm employed in this study. It out performs both Neural Network
and J48 decision tree algorithms with a classification accuracy of almost to the level of
perfection, 99.95% and the AUC value of 1, which reflects its perfect performances.
Also other comparison tools like Precision, TP rate, FP rate and Kappa shows the
supreme performance of the Random Forest over the J48 and neural network prediction
algorithms. Table 11 depicts that the true positive rate for classification of A, B, C and D
accurately shows that C is 100% correctly classified as C and  99.9% , 99.5% and
99.3% True Positive rate for  A, B and D respectively. Also the false positive rate is 0%
and much nearer to 0% to all of the classes. So that in classifying the CD4 count
change RF has been able to be superior to other J48 and Neural Network.
As table 15 presents, the most important attribute in classifying CD4 count change is
the age, the second most important was the educational status of the patient and
CD4/CD8 ratio at the start of ART. Other variables like Patient’s Cotrimoxasole
adherence, Patient’s Last Visit TB status and Patient’s Pregnancy during enrollment
have less information gain values. That means they contribute smaller in predicting the
CD4 count change than other variables shortlisted. Note that here; the information gain
measures the expected reduction in entropy due to splitting on a certain attribute. As an
example, the total entropy will be reduced by 0.281, when the classification on decision
tree spitted by educational status. That means knowing educational status of a patient
reduces the entropy by 0.281 and goes to the next splitting attribute in classifying the
CD4 count changes. So this information gain values show how much the splitting
attribute contribute in the classification of CD4 count changes.
All the three methods agree that Hemoglobin Level at Start of ART, CD4/CD8ratio, LFT,
Marital Status, Educational status, Patient Gender, Patient Age, Patient WHO Stage,
Patient Original regimen, Patient’s current regimen, Patient’s Cotrimoxasole adherence
and Time Gap/weeks are important in predicting CD4 count changes.
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Other studies elsewhere found comparable predictive performance accuracy to this
study. In a study done in 2011 in India to predict anti-tubercular molecules using
machine learning on high-throughput biological screening datasets, RF outperformed
other classification accuracies J48 and SVM classification by scoring accuracy greater
than 80%(29).
Also this study achieves better accuracy than a machine learning study done in South
Africa to forecast CD4 count change, in this study SVM scores accuracy of 83%(lower
in performance than this study)(20). This higher performance could be due to the
algorithm difference and the input variables used were higher in this study.
Also in another study done in UK to predict virologic response to ART found a result
that is RF and SVM models can produce predictions of virological response to HIV
treatment that are comparable in accuracy to a committee of ANN models. ANN models
were significantly inferior to RF and SVM (15). The result of our study is therefore in line
with this finding by achieving better accuracy by Random Forest. But it is very difficult to
extract rules or patterns and select variables using random forest. Therefore because of
the ease of interpretation, the j48 decision tree is taken as the best model to predict the
ranges of CD4 count changes.
A study done at Felege Hiwot Referral Hospital to predict adherence status of ART
clients found very good performance accuracy (93.14%) by J48 Decision tree
algorithm(32). But this study applies an extra algorithm; Random Forest, which
performed excellent in predicting the CD4 count changes better than decision tree and
Neural Network.
So that as this study is supported by other literatures, we can deduce that RF can
predict CD4 count changes in better accuracy than any other methods compared in this
study.
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7. STRENGTHS AND LIMITATIONS
The strength of this study is the extraction of data from both in the electronic data base
and patient clinical record. In addition more algorithms were employed for analysis
However, the study suffers from the following problems. Both of the data sources are
secondary source, therefore all the problems related with using secondary data applies
to this study
The data set has low number of instances and attributes, as it is generally accepted that
machine learning algorithms perform better if employed with large number of instances
and attributes.
This study didn’t include important variables that are known to be potentially affecting
CD4 count like Viral load, types of opportunistic infections and nutritional status of the
patient need to be included if better result is to be achieved.
More results which can learn medical data well should be tested. This study only
predicts CD4 count change in a certain range, algorithms that can predict the absolute
count like multiple linear regression should be tested.
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8. CONCLUSION
After trying many experiments in WEKA as depicted in the tables of the model building
section of the result part, RF is observed to have much better accuracy, an accuracy
which can be said very nearly close to perfect performance. So that we can deduce that
RF is the best working model, from all models tried in this study, to predict the CD4
count change that comes after the initiation of ART. To come up with this kind of result,
we observed that balancing the imbalanced dataset is in utmost importance in
upgrading the performances of different algorithms. But in random forest, it is very
difficult to extract rules and select variables; therefore because of ease of
interpretability, j48 decision tree is taken as the best working model.
Of all the 26 variables, the Ranker + InfoGainAttributeEval method of attribute
evaluation shows variables important in predicting the CD4 count change are Patient
Age, Educational status, CD4/CD8ratio at start of ART, CD8 cell count at the start of
ART, Patient original regimen, Patient current regimen, Hemoglobin level at start of
ART, Marital status, Patient’s gender, Patient’s initial CD4 count, Platelet count at start
of ART, Time Gap/weeks, Current Regimen Similarity With Original Regimen, Liver
function test, Employment status, and Patient’s WHO Stage are among the notables
with high information gain values.
Therefore with those variables listed in table 14 and using Random Forest or J48
decision tee algorithm, it is possible to predict CD4 count changes. And generally, we
can conclude that, modifying those variables can affect the CD4 count change that will
come after initiation of ART.
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9. RECOMMENDATIONS
Based on the result and the observed situations during data collection and cleaning, we
do like to forward the following recommendations to be considered in the health care
provision and future data mining research to CD4 count change prediction.
For data mining researchers
We do like to encourage data mining researchers consider the following if they wish to
predict CD4 count changes much more better than this study
Others studies if needed to employ machine learning tools to predict CD4 count change;
need to improve shortcomings of this study.
 It is essential to include more attributes
 It is also important include more instances
 More other algorithms need to be applied
 Try algorithms like multiple linear regression that can predict the absolute CD4
count change
 This type of study needs more time to apply more algorithms, because some
algorithms take much longer time to learn the data and give output.
For health care providers
As presented in Annex III, this study has come with interesting rules in predicting the
CD4 count change.  Thus, we would like to forward the following.
 J48 can be deployed to predict CD4 count changes
 J48 rules displayed in Annex III need to be used in predicting the CD4 count
changes
 These algorithm also need to be used for patient monitoring
For data base administrators
 Integrate the data base with clinical service
 Try to include more attributes, that are being written in the manual patient chart,
in the data base.
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11. ANNEX
I. Questionnaire
The purpose of this study is to forecast the range of CD4 count changes after initiation of ART
using the machine learning techniques. One data base administrator, two ART nurses in
collaboration with one card clerk will extract and collect the data. Most of the questions are
similar to the questions in ART register, but there are other attributes that are needed to predict
the range of CD4 count changes which are included here.
Patient identification
1. Patient MRN-----------------------
Socio demographic characteristics
2. Age at the start of ART (No. in yrs) --------------------
3. Gender
a. Male
b. Female
4. Place of residence
a. Rural
b. Urban
5. Marital Status
a. Single b. Married c. Separated d. Divorced e. Widow/Widower
6. Level of education
a. Unable to read and write b. Primary     c.  Secondary     d. Tertiary
7. Religion
a. Orthodox b. Muslim      c. Protestant d. Catholic e. Other specify-------------
8. Employment status
a. Employed b. Unemployed c. Self employed    d. other specify--------
HIV and ART related questions
9. When did the patient start ART? DD/mm/yyyy --------------------
10. Weight of the patient at the start of ART(kgs) --------------------
11. Functional status of the patient at the start of ART
a. Ambulatory b. Bedridden     c.  Working       d. Other specify----------------
12. WHO staging of the patient at the start of ART
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a. Stage 1
b. Stage 2
c. Stage 3
d. Stage 4
13. CD4 cell count at the start of ART ----------------------------------
14. CD8 count at the start of ART----------------------------------------
15. CD4/CD8 ratio at the start of ART------------------------------------
16. Hemoglobin level at the start of ART (in mg/dl) ----------------------------
17. Haematocrit at the start of ART------------------------------
18. SGOT at the start of ART-------------------------------------
19. SGPT at the start of ART--------------------------------------
Patients follow up information questions
20. Most recent follow up CD4 count-------------------------
21. Date when the most recent CD4 count was done (dd/mm/yyyy)--------------
22. Number of weeks from baseline to follow up CD4 count----------------------
23. Change in CD4 count = Baseline – most recent follow up CD4 count-----------------
24. Have the patient ever poorly adhered to ART?
a. Yes b. No if yes go to Q 29
25. Adherence status
a. Poor
b. Lost
c. Stop
d. Drop
e. Restarted
f. Other specify--------------
26. Is the regimen changed after starting ART?
a. Yes b. No
Questionnaire filled and Completed by              Approved by
Name---------------------------- Name-----------------------
Signature----------------------- Signature------------------
Date----------------------------- Date------------------------- Thank you!!
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ii. ARV INTAKE FORM
PATIENT REGISTRATION FORM
Health Facility
Name:_________________________________________________________________
Date:______/______/___________
PATIENT IDENTIFICATION
Name: ________ __ Father’s Name: _____ ____
__ _ Grandfather’s Name: ________
Date of Birth:______/______/_____    Age:_______ Gender: ○ Male
○ Female
ART Unique ID No.:
Patient Card No.: __________/__________
MARITAL STATUS: RELIGION: LEVEL OF EDUCATION:
○   Never Married ○    Muslim ○ No education
○   Married  incl. de facto) ○    Orthodox ○ Primary
○    Divorced ○    Separated ○ Secondary
○ Widow/Widower ○ Catholic ○ Tertiary
○   Protestant
○   Other
Occupation: ____________________________________________________________
HUSBAND / WIFE AND DEPENDENT CHILDREN AT HOME
○ Husband/Wife Children ○  Yes ○ No
If Yes:  Age
_____,______,______,______,______,______,
PATIENT ADDRESS
Region: ________________________ Woreda/Kifle Ketema:
______________________ __
Kebele/Peasant Association:
___________________________________________________________   House
No.:____________
Telephone Number: Home ____ Mobile:______
Work: ____________________
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iii. J48 Decision tree
J48 pruned tree
------------------
Patient_Age = A: C (3.0/1.0)
Patient_Age = B: D (5.0/1.0)
Patient_Age = C: D (30.0)
Patient_Age = D
|   MARITALSTATUS = Divorced
|   |   education = No: C (6.0/1.0)
|   |   education = Primary: B (22.0/3.0)
|   |   education = Secondary: B (1.0)
|   |   education = Teritiary: C (1.0)
|   MARITALSTATUS = Married: C (248.0/5.0)
|   MARITALSTATUS = Separated: B (4.0/1.0)
|   MARITALSTATUS = Single: C (7.0/1.0)
|   MARITALSTATUS = Widow/widower: C (7.0/2.0)
Patient_Age = E
|   LFT = N
|   |   Patient_FunctionalStatus = W
|   |   |   Patient_OriginalRegimen = AZT-3TC-EFV: A (16.0/3.0)
|   |   |   Patient_OriginalRegimen = AZT-3TC-EFVKid: B (0.0)
|   |   | Patient_OriginalRegimen = AZT-3TC-NVP
|   |   |   |   Patient_Gender = Male: A (68.0)
|   |   |   |   Patient_Gender = Female
|   |   |   |   |   Patient_WHOStage = I: A (5.0/1.0)
|   |   |   |   |   Patient_WHOStage = II
|   |   |   |   |   |   education = No
|   |   |   |   |   |   |   MARITALSTATUS = Divorced: B (127.0/2.0)
|   |   |   |   |   |   |   MARITALSTATUS = Married
|   |   |   |   |   |   |   |   CD8_cellcount_at_theStartof_ART <= 489.161753: A (6.0/1.0)
|   |   |   |   |   |   |   |   CD8_cellcount_at_theStartof_ART > 489.161753: B (35.0/2.0)
|   |   |   |   |   |   |   MARITALSTATUS = Separated: B (0.0)
|   |   |   |   |   |   |   MARITALSTATUS = Single: B (0.0)
|   |   |   |   |   |   |   MARITALSTATUS = Widow/widower: B (0.0)
|   |   | |   |   |   education = Primary: A (2.0)
|   |   |   |   |   |   education = Secondary: B (207.0)
|   |   |   |   |   |   education = Teritiary: B (0.0)
|   |   |   |   |   Patient_WHOStage = III
|   |   |   |   |   |   Patient_Regimen = AZT-3TC-EFV
|   | |   |   |   |   |   MARITALSTATUS = Divorced: B (168.0)
|   |   |   |   |   |   |   MARITALSTATUS = Married
|   |   |   |   |   |   |   |   CD4/CD8ratio_AtStartof_ART <= 0.070048: B (18.0)
|   |   |   |   |   |   |   |   CD4/CD8ratio_AtStartof_ART > 0.070048: A (5.0/1.0)
|   |   |   |   |   |   |   MARITALSTATUS = Separated: B (0.0)
|   |   |   |   |   |   |   MARITALSTATUS = Single: B (1.0)
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|   |   |   |   |   |   |   MARITALSTATUS = Widow/widower: A (1.0)
|   |   |   |   |   |   Patient_Regimen = AZT-3TC-NVP
|   |   |   |   |   |   |   Patient_CD4CountAdult <= 134.873084
|   |   |   |   |   |   |   |   HgbLevel_atStart <= 12.011794: A (22.0/3.0)
|   |   |   |   |   |   |   |   HgbLevel_atStart > 12.011794
|   |   |   |   |   |   |   |   |   Patient_Weight <= 38.814895: A (8.0/3.0)
|   |   |   |   |   |   |   |   |   Patient_Weight > 38.814895
|   |   |   |   |   |   |   |   |   |   EMPLOYEMENT = E: B (74.0)
|   |   |   |   |   |   |   |   |   |   EMPLOYEMENT = Farmer: B (0.0)
|   |   |   |   |   |   |   | |   |   EMPLOYEMENT = NE
|   |   |   |   |   |   |   |   |   |   |   education = No: B (54.0/3.0)
|   |   |   |   |   |   |   |   |   |   |   education = Primary: A (10.0/1.0)
|   |   |   |   |   |   |   |   |   |   |   education = Secondary
|   |   | |   |   |   |   |   |   |   |   |   TimeGap/weeks <= 179.990248: B (147.0)
|   |   |   |   |   |   |   |   |   |   |   |   TimeGap/weeks > 179.990248: A (5.0/1.0)
|   |   |   |   |   |   |   |   |   |   |   education = Teritiary: B (0.0)
|   |   |   |   | |   |   |   |   |   EMPLOYEMENT = Retired: B (0.0)
|   |   |   |   |   |   |   |   |   |   EMPLOYEMENT = SE: B (0.0)
|   |   |   |   |   |   |   Patient_CD4CountAdult > 134.873084: A (62.0)
|   |   |   |   |   |   Patient_Regimen = AZT-3TC-EFVKid: B (0.0)
|   |   |   |   |   |   Patient_Regimen = d4t(30)-3TC-EFV: B (0.0)
|   |   |   |   |   |   Patient_Regimen = d4t(30)-3TC-NVP: A (2.0/1.0)
|   |   |   |   |   |   Patient_Regimen = DROP: B (0.0)
|   |   |   |   |   |   Patient_Regimen = LOST: B (0.0)
| |   |   |   |   |   Patient_Regimen = OTHER: A (30.0/2.0)
|   |   |   |   |   |   Patient_Regimen = RESTART: B (0.0)
|   |   |   |   |   Patient_WHOStage = IV: A (2.0)
|   |   |   Patient_OriginalRegimen = AZT-3TC-NVPKid: B (0.0)
|   |   |   Patient_OriginalRegimen = d4t(30)-3TC-EFV
|   |   |   |   MARITALSTATUS = Divorced: A (11.0/2.0)
|   |   |   |   MARITALSTATUS = Married: B (604.0/2.0)
|   |   |   |   MARITALSTATUS = Separated: B (0.0)
|   |   |   |   MARITALSTATUS = Single: B (0.0)
|   |   |   |   MARITALSTATUS = Widow/widower: B (24.0/1.0)
|   |   |   Patient_OriginalRegimen = d4t(30)-3TC-NVP
|   |   |   |   CD8_cellcount_at_theStartof_ART <= 983.181474
|   |   |   |   |   education = No
|   |   |   |   |   |   Patient_CD4CountAdult <= 85.179529: A (5.0)
|   |   |   |   |   |   Patient_CD4CountAdult > 85.179529: B (111.0/1.0)
|   |   |   |   |   education = Primary: A (5.0/1.0)
|   |   |   |   |   education = Secondary: B (9.0/4.0)
|   |   |   |   |   education = Teritiary: B (0.0)
|   |   |   |   CD8_cellcount_at_theStartof_ART > 983.181474: A (50.0/6.0)
|   |   |   Patient_OriginalRegimen = d4t(40)-3TC-EFV: A (1.0)
|   |   |   Patient_OriginalRegimen = d4t(40)-3TC-NVP: B (0.0)
|   |   |   Patient_OriginalRegimen = OTHER: A (27.0/4.0)
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|   |   Patient_FunctionalStatus = A
|   |   |   MARITALSTATUS = Divorced: A (14.0)
|   |   |   MARITALSTATUS = Married
|   |   |   |   Patient_Gender = Male: A (5.0/1.0)
|   |   |   |   Patient_Gender = Female: B (15.0/2.0)
|   |   |   MARITALSTATUS = Separated: A (1.0)
|   |   |   MARITALSTATUS = Single: A (7.0/2.0)
|   |   |   MARITALSTATUS = Widow/widower
|   |   |   |   Patient_CD4CountAdult <= 113: B (5.0/2.0)
|   |   |   |   Patient_CD4CountAdult > 113: A (5.0)
|   |   Patient_FunctionalStatus = B: A (8.0/1.0)
|   LFT = Elevated
|   |   CD4/CD8ratio_AtStartof_ART <= 0.264983: A (71.0/16.0)
|   |   CD4/CD8ratio_AtStartof_ART > 0.264983: B (9.0/1.0)
Patient_Age = F
|   Patient_Gender = Male
|   |   Patient_FunctionalStatus = W: A (930.0/7.0)
|   |   Patient_FunctionalStatus = A
|   |   |   Residence = G: A (64.0/1.0)
|   |   |   Residence = O
|   |   |   |   LFT = N
|   |   |   |   |   Patient_OriginalRegimen = AZT-3TC-EFV: D (0.0)
|   |   |   |   |   Patient_OriginalRegimen = AZT-3TC-EFVKid: D (0.0)
|   |   |   |   | Patient_OriginalRegimen = AZT-3TC-NVP: D (78.0/1.0)
|   |   |   |   |   Patient_OriginalRegimen = AZT-3TC-NVPKid: D (0.0)
|   |   |   |   |   Patient_OriginalRegimen = d4t(30)-3TC-EFV: D (0.0)
|   |   |   |   |   Patient_OriginalRegimen = d4t(30)-3TC-NVP: A (3.0)
|   |   |   |   |   Patient_OriginalRegimen = d4t(40)-3TC-EFV: D (0.0)
|   |   |   |   |   Patient_OriginalRegimen = d4t(40)-3TC-NVP: D (0.0)
|   |   |   |   |   Patient_OriginalRegimen = OTHER: D (16.0/1.0)
|   |   |   |   LFT = Elevated: A (6.0)
|   |   Patient_FunctionalStatus = B: A (9.0)
|   Patient_Gender = Female
|   |   EMPLOYEMENT = E: A (61.0/5.0)
|   |   EMPLOYEMENT = Farmer: A (3.0)
|   |   EMPLOYEMENT = NE
|   |   |   education = No
|   |   |   |   Patient_WHOStage = I: A (14.0/1.0)
| |   |   |   Patient_WHOStage = II
|   |   |   |   |   Patient_OriginalRegimen = AZT-3TC-EFV: A (1.0)
|   |   |   |   |   Patient_OriginalRegimen = AZT-3TC-EFVKid: D (0.0)
|   |   |   |   |   Patient_OriginalRegimen = AZT-3TC-NVP
|   |   |   |   |   |   LFT = N: A (33.0)
|   |   |   |   |   |   LFT = Elevated
|   |   |   |   |   |   |   CD4/CD8ratio_AtStartof_ART <= 0.096124: D (10.0)
|   |   |   |   |   |   |   CD4/CD8ratio_AtStartof_ART > 0.096124: A (8.0/3.0)
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|   |   |   |   |   Patient_OriginalRegimen = AZT-3TC-NVPKid: D (0.0)
|   |   |   |   |   Patient_OriginalRegimen = d4t(30)-3TC-EFV: A (2.0)
|   |   |   |   |   Patient_OriginalRegimen = d4t(30)-3TC-NVP: A (10.0)
|   |   |   |   |   Patient_OriginalRegimen = d4t(40)-3TC-EFV: D (0.0)
|   |   |   | |   Patient_OriginalRegimen = d4t(40)-3TC-NVP: A (1.0)
|   |   |   |   |   Patient_OriginalRegimen = OTHER: D (423.0/3.0)
|   |   |   |   Patient_WHOStage = III
|   |   |   |   |   CD8_cellcount_at_theStartof_ART <= 848.146341
|   |   |   |   |   |   Patient_Regimen = AZT-3TC-EFV
|   |   |   |   |   |   |   MARITALSTATUS = Divorced: D (166.0/3.0)
|   |   |   |   |   |   |   MARITALSTATUS = Married: A (10.0)
|   |   |   |   |   |   |   MARITALSTATUS = Separated: D (0.0)
|   |   |   |   |   |   |   MARITALSTATUS = Single: D (1.0)
|   |   |   |   |   |   |   MARITALSTATUS = Widow/widower: A (1.0)
|   |   |   |   |   |   Patient_Regimen = AZT-3TC-NVP
|   |   |   |   |   |   |   platletatthestart <= 273.266417
|   |   |   |   |   |   |   |   Patient_FunctionalStatus = W: A (34.0/3.0)
|   |   |   |   |   |   |   |   Patient_FunctionalStatus = A: D (13.0/3.0)
|   |   |   |   |   |   |   |   Patient_FunctionalStatus = B: B (1.0)
|   |   |   |   |   |   |   platletatthestart > 273.266417
|   |   |   |   |   |   |   | TimeGap/weeks <= 213.902961: D (92.0/4.0)
|   |   |   |   |   |   |   |   TimeGap/weeks > 213.902961
|   |   |   |   |   |   |   |   |   HgbLevel_atStart <= 10.287374: D (5.0)
|   |   |   |   |   |   |   |   |   HgbLevel_atStart > 10.287374: A (15.0/1.0)
|   |   |   |   |   |   Patient_Regimen = AZT-3TC-EFVKid: D (0.0)
|   |   |   |   |   |   Patient_Regimen = d4t(30)-3TC-EFV: A (1.0)
|   |   |   |   |   |   Patient_Regimen = d4t(30)-3TC-NVP: A (5.0)
|   |   |   |   |   |   Patient_Regimen = DROP: D (0.0)
|   |   |   |   |   |   Patient_Regimen = LOST: D (0.0)
|   |   |   |   |   |   Patient_Regimen = OTHER
|   |   |   |   |   |   |   Patient_CD4CountAdult <= 65.891291
|   |   |   |   |   |   |   |   Residence = G: A (12.0)
|   |   |   |   |   |   |   | Residence = O: D (5.0)
|   |   |   |   |   |   |   Patient_CD4CountAdult > 65.891291
|   |   |   |   |   |   |   |   MARITALSTATUS = Divorced
|   |   |   |   |   |   |   |   |   TimeGap/weeks <= 192.480141
|   |   |   |   |   |   |   |   |   |   HgbLevel_atStart <= 11.499182: D (13.0/1.0)
|   |   |   |   |   |   |   |   |   |   HgbLevel_atStart > 11.499182: A (8.0/1.0)
|   |   |   |   |   |   |   |   |   TimeGap/weeks > 192.480141: D (44.0)
|   |   |   |   |   |   |   |   MARITALSTATUS = Married
|   |   | |   |   |   |   |   |   platletatthestart <= 313.964633
|   |   |   |   |   |   |   |   |   |   platletatthestart <= 220.068083
|   |   |   |   |   |   |   |   |   |   |   HgbLevel_atStart <= 12.696238: D (8.0)
|   |   |   |   |   |   |   |   |   |   | HgbLevel_atStart > 12.696238: A (5.0/2.0)
|   |   |   |   |   |   |   |   |   |   platletatthestart > 220.068083
|   |   |   |   |   |   |   |   |   |   |   HgbLevel_atStart <= 9.236521
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|   |   |   |   |   |   |   |   |   |   |   |   CurrentRegimenSimilarWithOriginalRegimen = No: A
(5.0/1.0)
|   |   |   |   |   |   |   |   |   |   |   |   CurrentRegimenSimilarWithOriginalRegimen = Yes: D
(9.0)
|   |   |   |   |   |   |   |   |   |   |   HgbLevel_atStart > 9.236521: D (481.0/1.0)
|   |   |   |   |   |   | |   |   platletatthestart > 313.964633
|   |   |   |   |   |   |   |   |   |   Patient_CD4CountAdult <= 112.529408: D (15.0/1.0)
|   |   |   |   |   |   |   |   |   |   Patient_CD4CountAdult > 112.529408: A (8.0/2.0)
|   |   |   |   |   |   |   |   MARITALSTATUS = Separated: D (0.0)
|   |   |   |   |   |   |   |   MARITALSTATUS = Single: A (2.0)
|   |   |   |   |   |   |   |   MARITALSTATUS = Widow/widower: A (4.0)
|   |   |   |   |   |   Patient_Regimen = RESTART: D (0.0)
|   |   |   |   |   CD8_cellcount_at_theStartof_ART > 848.146341
|   |   |   |   |   |   Patient_FunctionalStatus = W
|   |   |   |   |   |   |   Residence = G
|   |   |   |   |   |   |   |   Patient_CD4CountAdult <= 188.381502: A (132.0/1.0)
|   |   |   |   |   |   |   |   Patient_CD4CountAdult > 188.381502
|   |   |   |   |   |   |   |   |   Patient_CD4CountAdult <= 223.142012
|   |   |   |   |   |   |   |   |   |   MARITALSTATUS = Divorced
|   |   |   |   |   |   |   |   |   |   |   TimeGap/weeks <= 158.462054: A (5.0)
|   |   |   |   | |   |   |   |   |   |   TimeGap/weeks > 158.462054: D (40.0/2.0)
|   |   |   |   |   |   |   |   |   |   MARITALSTATUS = Married: A (7.0)
|   |   |   |   |   |   |   |   |   |   MARITALSTATUS = Separated: D (0.0)
|   |   |   |   |   |   |   |   |   |   MARITALSTATUS = Single: D (0.0)
|   |   |   |   |   |   |   |   |   |   MARITALSTATUS = Widow/widower: D (0.0)
|   |   |   |   |   |   |   |   |   Patient_CD4CountAdult > 223.142012: A (26.0)
|   |   |   |   |   |   |   Residence = O
|   |   |   |   |   | |   |   LFT = N: A (5.0/1.0)
|   |   |   |   |   |   |   |   LFT = Elevated: D (37.0/1.0)
|   |   |   |   |   |   Patient_FunctionalStatus = A
|   |   |   |   |   |   |   CurrentRegimenSimilarWithOriginalRegimen = No: A (7.0)
|   |   |   |   |   |   |   CurrentRegimenSimilarWithOriginalRegimen = Yes
|   |   |   |   |   |   |   |   MARITALSTATUS = Divorced: D (96.0/2.0)
|   |   |   |   |   |   |   |   MARITALSTATUS = Married: D (5.0/1.0)
|   |   |   |   |   |   |   |   MARITALSTATUS = Separated: A (1.0)
| |   |   |   |   |   |   |   MARITALSTATUS = Single: D (16.0)
|   |   |   |   |   |   |   |   MARITALSTATUS = Widow/widower: A (3.0)
|   |   |   |   |   |   Patient_FunctionalStatus = B: A (1.0)
|   |   |   |   Patient_WHOStage = IV
|   |   |   |   |   platletatthestart <= 482: A (112.0/1.0)
|   |   |   |   |   platletatthestart > 482: D (7.0/1.0)
|   |   |   education = Primary
|   |   |   |   CD8_cellcount_at_theStartof_ART <= 907.423887
|   |   |   |   |   Patient_WHOStage = I: A (5.0)
|   |   |   |   | Patient_WHOStage = II: A (15.0/2.0)
|   |   |   |   |   Patient_WHOStage = III
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|   |   |   |   |   |   Patient_OriginalRegimen = AZT-3TC-EFV: A (8.0/1.0)
|   |   |   |   |   |   Patient_OriginalRegimen = AZT-3TC-EFVKid: D (0.0)
|   |   |   |   |   |   Patient_OriginalRegimen = AZT-3TC-NVP
|   |   |   |   |   |   |   CD8_cellcount_at_theStartof_ART <= 525.050481
|   |   |   |   |   |   |   |   MARITALSTATUS = Divorced: D (0.0)
|   |   |   |   |   |   |   |   MARITALSTATUS = Married: D (141.0/4.0)
|   |   | |   |   |   |   |   MARITALSTATUS = Separated: D (0.0)
|   |   |   |   |   |   |   |   MARITALSTATUS = Single: A (9.0/1.0)
|   |   |   |   |   |   |   |   MARITALSTATUS = Widow/widower: D (0.0)
|   |   |   |   |   |   |   CD8_cellcount_at_theStartof_ART > 525.050481: A (25.0/1.0)
|   |   |   |   |   |   Patient_OriginalRegimen = AZT-3TC-NVPKid: D (0.0)
|   |   |   |   |   |   Patient_OriginalRegimen = d4t(30)-3TC-EFV: A (18.0)
|   |   |   |   |   |   Patient_OriginalRegimen = d4t(30)-3TC-NVP: A (20.0)
| |   |   |   |   |   Patient_OriginalRegimen = d4t(40)-3TC-EFV: D (0.0)
|   |   |   |   |   |   Patient_OriginalRegimen = d4t(40)-3TC-NVP: D (0.0)
|   |   |   |   |   |   Patient_OriginalRegimen = OTHER
|   |   |   |   |   |   |   MARITALSTATUS = Divorced: D (120.0/2.0)
|   |   |   |   |   |   |   MARITALSTATUS = Married
|   |   |   |   |   |   |   |   CD4/CD8ratio_AtStartof_ART <= 0.223306: A (6.0/2.0)
|   |   |   |   |   |   |   |   CD4/CD8ratio_AtStartof_ART > 0.223306: D (10.0)
|   |   |   |   |   | |   MARITALSTATUS = Separated: D (0.0)
|   |   |   |   |   |   |   MARITALSTATUS = Single: D (0.0)
|   |   |   |   |   |   |   MARITALSTATUS = Widow/widower: A (1.0)
|   |   |   |   |   Patient_WHOStage = IV: A (13.0/2.0)
|   |   |   |   CD8_cellcount_at_theStartof_ART > 907.423887: A (134.0/2.0)
|   |   |   education = Secondary
|   |   |   |   TimeGap/weeks <= 87.153499
|   |   |   |   |   Patient_OriginalRegimen = AZT-3TC-EFV: A (5.0/1.0)
|   |   |   |   |   Patient_OriginalRegimen = AZT-3TC-EFVKid: A (0.0)
|   |   |   |   |   Patient_OriginalRegimen = AZT-3TC-NVP: D (8.0)
|   |   |   |   |   Patient_OriginalRegimen = AZT-3TC-NVPKid: A (0.0)
|   |   |   |   |   Patient_OriginalRegimen = d4t(30)-3TC-EFV: A (1.0)
|   |   |   |   |   Patient_OriginalRegimen = d4t(30)-3TC-NVP: A (9.0/1.0)
|   |   |   |   |   Patient_OriginalRegimen = d4t(40)-3TC-EFV: A (0.0)
|   |   |   |   |   Patient_OriginalRegimen = d4t(40)-3TC-NVP: A (0.0)
|   |   |   |   |   Patient_OriginalRegimen = OTHER: A (1.0)
|   |   |   |   TimeGap/weeks > 87.153499: A (218.0/7.0)
|   |   |   education = Teritiary: A (32.0)
|   |   EMPLOYEMENT = Retired: D (0.0)
|   |   EMPLOYEMENT = SE: A (33.0)
Patient_Age = G
|   education = No
|   |   MARITALSTATUS = Divorced
|   |   |   LFT = N
|   |   |   | CurrentRegimenSimilarWithOriginalRegimen = No
|   |   |   |   |   Patient_OriginalRegimen = AZT-3TC-EFV: D (44.0/2.0)
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|   |   |   |   |   Patient_OriginalRegimen = AZT-3TC-EFVKid: B (0.0)
|   |   |   |   |   Patient_OriginalRegimen = AZT-3TC-NVP
|   |   | |   |   |   CD8_cellcount_at_theStartof_ART <= 715.452718
|   |   |   |   |   |   |   Patient_Regimen = AZT-3TC-EFV: A (1.0)
|   |   |   |   |   |   |   Patient_Regimen = AZT-3TC-NVP: A (8.0/3.0)
|   |   |   |   |   |   |   Patient_Regimen = AZT-3TC-EFVKid: C (0.0)
|   |   |   |   |   |   |   Patient_Regimen = d4t(30)-3TC-EFV: C (0.0)
|   |   |   |   |   |   |   Patient_Regimen = d4t(30)-3TC-NVP: C (0.0)
|   |   |   |   |   |   |   Patient_Regimen = DROP: C (0.0)
|   |   |   |   |   |   |   Patient_Regimen = LOST: C (0.0)
|   |   |   |   |   |   |   Patient_Regimen = OTHER: C (48.0/3.0)
|   |   |   |   |   |   |   Patient_Regimen = RESTART: C (0.0)
|   |   |   |   |   |   CD8_cellcount_at_theStartof_ART > 715.452718
|   |   |   |   |   |   |   Patient_Gender = Male: A (11.0/1.0)
|   |   |   |   |   |   |   Patient_Gender = Female
|   |   |   |   |   |   |   |   Patient_WHOStage = I: A (1.0)
|   |   |   |   |   |   |   |   Patient_WHOStage = II: C (1.0)
|   |   |   |   |   |   |   |   Patient_WHOStage = III
|   |   |   |   |   |   |   |   |   CD8_cellcount_at_theStartof_ART <= 1294.62801: B (249.0/6.0)
|   |   |   |   |   |   |   |   |   CD8_cellcount_at_theStartof_ART > 1294.62801: C (32.0/2.0)
|   |   |   |   |   |   |   |   Patient_WHOStage = IV: B (299.0)
|   |   |   |   |   Patient_OriginalRegimen = AZT-3TC-NVPKid: B (0.0)
|   |   |   |   |   Patient_OriginalRegimen = d4t(30)-3TC-EFV: B (106.0/4.0)
|   |   |   |   |   Patient_OriginalRegimen = d4t(30)-3TC-NVP
|   |   |   |   |   |   CD8_cellcount_at_theStartof_ART <= 1123.291012
|   |   |   |   |   |   |   platletatthestart <= 342.881723
|   |   |   |   |   |   |   |   HgbLevel_atStart <= 14.303065: B (255.0/2.0)
|   |   |   |   |   |   |   |   HgbLevel_atStart > 14.303065
|   |   |   |   |   |   |   | |   Patient_Regimen = AZT-3TC-EFV: B (10.0)
|   |   |   |   |   |   |   |   |   Patient_Regimen = AZT-3TC-NVP: B (0.0)
|   |   |   |   |   |   |   |   |   Patient_Regimen = AZT-3TC-EFVKid: B (0.0)
|   |   |   |   |   |   |   |   |   Patient_Regimen = d4t(30)-3TC-EFV: B (0.0)
|   |   |   |   |   |   |   |   |   Patient_Regimen = d4t(30)-3TC-NVP: B (0.0)
|   |   |   |   |   |   |   |   |   Patient_Regimen = DROP: B (0.0)
|   |   |   |   |   |   |   |   |   Patient_Regimen = LOST: B (0.0)
|   |   |   |   |   | |   |   |   Patient_Regimen = OTHER: D (6.0)
|   |   |   |   |   |   |   |   |   Patient_Regimen = RESTART: B (0.0)
|   |   |   |   |   |   |   platletatthestart > 342.881723
|   |   |   |   |   |   |   |   Patient_CD4CountAdult <= 156.049435: B (5.0/2.0)
|   |   |   |   |   |   |   |   Patient_CD4CountAdult > 156.049435: D (13.0)
|   |   |   |   |   |   CD8_cellcount_at_theStartof_ART > 1123.291012
|   |   |   |   |   |   |   platletatthestart <= 207.786547: B (13.0)
|   |   |   |   |   |   |   platletatthestart > 207.786547
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|   |   |   |   |   |   |   |   HgbLevel_atStart <= 13.060457
|   |   |   |   |   |   |   |   |   TimeGap/weeks <= 200.96491: D (16.0)
|   |   |   |   |   |   |   |   |   TimeGap/weeks > 200.96491: C (9.0/2.0)
|   |   |   |   | |   |   |   HgbLevel_atStart > 13.060457: C (82.0)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|   |   |   |   |   CD8_cellcount_at_theStartof_ART > 593: B (5.0/2.0)
|   |   |   |   CD8_cellcount_at_theStartof_ART > 666.275824: A (26.0)
|   |   |   education = Teritiary: A (11.0)
|   |   Patient_Regimen = RESTART: D (0.0)
Patient_Age = I: A (973.0)
Patient_Age = J: A (478.0)
Patient_Age = K: A (265.0)
Number of Leaves  : 951
Size of the tree : 1421
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iv. Information sheet
Title of the research project: - Predicting CD4 count changes in ART clients using the
data mining approach in Gondar University Hospital
Name of the investigator: - Mihiretu Molla
Name of the organization: - University of Gondar, Collge of medicine and health
Science, Institute of Public health
Introduction: - This information sheet was prepared for University of Gondar,
University of Gondar Hospital administration and the hospital’s ART program
coordinator’s office to make these concerned bodies clear about the purpose of the
research project, data collection procedures to get permission to conduct the research.
Purpose of the research project: - is to forecast the range of CD4 count changes after
initiation of ART, which is very helpful to look further to our client’s future and to make
some recommendations to our client for better progress and improvement initially and
for better management and resource allocation.
Procedure: - In order to attain the above mentioned objective, all adults who started
ART and have baseline and follow up CD4 count was included in this study.
Risk/or Discomfort and Benefits: - By participating in this project, the subjects of this
secondary data will have almost no risk or harm, and the benefit of reviewing their
document is utmost importance for monitoring their progress and response to therapy.
Therefore patients will benefit directly individually or collectively.
Confidentiality: - To maintain confidentiality anonymous electronic copy of the ART
data sets was received from the ART clinic data base and it was supplemented by the
manually extracted documents which are collected by the ART nurses and card clerk
working collaboratively.  The information collected for the purpose of this research are
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kept highly confidential and it is shared to nobody, by keeping this document in
accessible to anybody.
Person to Contact:- This research project was reviewed and approved by the
institutional board of college of Medicine and Health Sciences, University of Gondar. If
you want to contact and know more about the research project, you can use the
following contact information.
1. Mr Mihiretu Molla
Tel +251913173333/ email mihiretaabush@gmail.com
2. Dr Desalegn Zegeye (MD, MPH), University of Gondar, College of medicine and
Health Sciences, institute of Public Health: Advisor
Tel. +251 912 02 37 54/ email zdesalegn@gmail.com
3. Dr Berihun Megabiaw (MD, MPH), University of Gondar, College of medicine and
Health Sciences, institute of Public Health: Advisor
Tel. +251 912 12 71 73/email beredomega@gmail.com
Permission: - Finally the investigator is given permission from your organization to
conduct this research, and the investigator immediately started cooperation with the
data collectors and started the research undertaking process.
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